

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES

? ds

Set	Items	Description
S1	35	E13-E15
S2	206	AU='LYMAN S D'
S3	274	E1-E8
S4	26	E15-E16
S5	181	AU='LYNCH D H'
S6	228	(S1 OR S2 OR S3 OR S4 OR S5) AND (FLT?)
S7	161	RD S6 (unique items)
S8	10	S7 AND (INFECT? OR BACTERI?)
S9	10	RD S8 (unique items)
S10	62	(FLT3?) (20N) (TREAT? OR THERAP? OR PREVENT? OR INHIBIT? OR - SUPPRESS?) (10N) (INFECT?)
S11	39	RD S10 (unique items)

? s (Flt3?) (20n) (treat? or therap? or prevent? or inhibit? or
suppress?) (10n) (bacteri? or viral or virus? or pathogen?)

Processing

Processing

Processing

Processing

	7614	FLT3?
	7690865	TREAT?
	7265769	THERAP?
	2524532	PREVENT?
	4650601	INHIBIT?
	968435	SUPPRESS?
	3758317	BACTERI?
	871420	VIRAL
	2004480	VIRUS?
	1411725	PATHOGEN?
S12	95	(FLT3?) (20N) (TREAT? OR THERAP? OR PREVENT? OR INHIBIT? OR SUPPRESS?) (10N) (BACTERI? OR VIRAL OR VIRUS? OR PATHOGEN?)

? rd s12

S13 55 RD S12 (unique items)

? t s13/3/all

13/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0016095269 BIOSIS NO.: 200600440664

The long-term but not the short-term antiviral effect of IFN-alpha depends
on Flt3 ligand and pDC

AUTHOR: Vollstedt Sabine; OKeefe Meredith; Ryf Beat; Glanzmann Bettina;
Hochrein Hubertus; Suter Mark (Reprint)

AUTHOR ADDRESS: Univ Zurich, Inst Virol, Winterthurerstr 266A, CH-8057
Zurich, Switzerland**Switzerland

AUTHOR E-MAIL ADDRESS: m.suter@vetadm.unizh.ch

JOURNAL: European Journal of Immunology 36 (5): p1231-1240 MAY 2006 2006

ISSN: 0014-2980

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

13/3/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0016069502 BIOSIS NO.: 200600414897

Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies

AUTHOR: Oveland Eystein; Fladmark Kari E; Wergeland Line; Gjertsen Bjern Tore; Hovland Randi (Reprint)

AUTHOR ADDRESS: Haukeland Univ Hosp, Ctr Med Genet and Mol Med, Helse Bergen HF, N-5021 Bergen, Norway**Norway

AUTHOR E-MAIL ADDRESS: randi.hovland@helse-bergen.no

JOURNAL: Current Pharmaceutical Biotechnology 7 (3): p185-198 JUN 2006 2006

ISSN: 1389-2010

DOCUMENT TYPE: Article; Literature Review

RECORD TYPE: Abstract

LANGUAGE: English

13/3/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015838202 BIOSIS NO.: 200600183597

Tyrosine phosphoproteomics of FLT3 signaling

AUTHOR: Gu Tinglei (Reprint); Nardone Julie; Lee Kim; Gygi Steven; Rush John; Comb Michael; Polakiewicz Roberto

AUTHOR ADDRESS: Cell Signaling Technol Inc, Canc Biol, Beverly, MA USA**USA

JOURNAL: Blood 106 (11, Part 1): p357A NOV 16 2005 2005

CONFERENCE/MEETING: 47th Annual Meeting of the American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005; 20051210

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

13/3/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015575995 BIOSIS NO.: 200510270495

Heat shock protein 90 (Hsp90) inhibition results in apoptotic killing of primary AML cells with FLT3/ITD mutation.

AUTHOR: Al-Shaer Laila M (Reprint); Gilkes Amanda F; Mills Kenneth I; Burnett Alan K; Rowntree Clare J

AUTHOR ADDRESS: Univ Wales Coll Cardiff, Sch Med, Dept Haematol, Cardiff, S Glam, UK**UK

JOURNAL: Blood 104 (11, Part 1): p692A NOV 16 2004 2004

CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

13/3/5 (Item 5 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015573520 BIOSIS NO.: 200510268020

Acceleration and enhancement of T-cell recovery and immune competence by Flt3-ligand (Flt3L) following BMT with low numbers of progenitor cells in immune deficient mice.

AUTHOR: Wils Evert-Jan (Reprint); Broers Annoek E C; Verjans Georges M G M; Niesters Bert; Osterhaus Albert D M E; Spits Hergen; Lowenberg Bob; Wagemaker Gerard; Braakman Erik; Cornelissen Jan J

AUTHOR ADDRESS: Erasmus Univ, Ctr Med, Rotterdam, Netherlands**Netherlands

JOURNAL: Blood 104 (11, Part 1): p17A NOV 16 2004 2004

CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

13/3/6 (Item 6 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015479879 BIOSIS NO.: 200510174379

Drug therapy for acute myeloid leukemia

AUTHOR: Tallman Martin S (Reprint); Gilliland D Gary; Rowe Jacob M

AUTHOR ADDRESS: Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehensive Canc Ctr, Dept Med, Div Hematol Oncol, 676 N St Clair St, Ste 850, Chicago, IL 60611 USA**USA

AUTHOR E-MAIL ADDRESS: m-tallman@northwestern.edu

JOURNAL: Blood 106 (4): p1154-1163 AUG 15 2005 2005

ISSN: 0006-4971

DOCUMENT TYPE: Article; Literature Review

RECORD TYPE: Abstract

LANGUAGE: English

13/3/7 (Item 7 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015392993 BIOSIS NO.: 200510087493

Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy

AUTHOR: Bernt Kathrin Maria (Reprint); Ni Shaoheng; Tieu Anh-Thu; Lieber Andre

AUTHOR ADDRESS: Univ Washington, Div Med Genet, Box 357720, Seattle, WA 98195 USA**USA

AUTHOR E-MAIL ADDRESS: tieua@student.ethz.ch

JOURNAL: Cancer Research 65 (10): p4343-4352 MAY 15 05 2005

ISSN: 0008-5472

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

13/3/8 (Item 8 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015286804 BIOSIS NO.: 200500193869

Increased blood myeloid dendritic cells and dendritic cell-poiectins in Langerhans cell histiocytosis

AUTHOR: Rolland Alexandre; Guyon Lydie; Gill Michelle; Cai Yi-Hong;
Banchereau Jacques; McClain Kenneth; Palucka A Karolina (Reprint)
AUTHOR ADDRESS: Baylor Inst Immunol Res, 3434 Live Oak, Dallas, TX, 75204,
USA**USA
AUTHOR E-MAIL ADDRESS: kmcclain@txccc.org; karolinp@baylorhealth.edu
JOURNAL: Journal of Immunology 174 (5): p3067-3071 March 1, 2005 2005
MEDIUM: print
ISSN: 0022-1767 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

13/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0015234870 BIOSIS NO.: 200500141935
Enhancement of dendritic cell production by Fms-like tyrosine kinase-3
ligand increases the resistance of mice to a burn wound infection
AUTHOR: Toliver-Kinsky Tracy E (Reprint); Cui Weihua; Murphey Erle D; Lin
Chengyie; Sherwood Edward R
AUTHOR ADDRESS: Med BranchDept Anesthesiol, Univ Texas, 301 Univ Blvd,
Galveston, TX, 77555, USA**USA
AUTHOR E-MAIL ADDRESS: ttoliver@utmb.edu
JOURNAL: Journal of Immunology 174 (1): p404-410 January 1, 2005 2005
MEDIUM: print
ISSN: 0022-1767 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

13/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0015148206 BIOSIS NO.: 200500055271
Both soluble and membrane-bound forms of Flt3 ligand enhance tumor immunity
following "suicide" gene therapy in a murine colon carcinoma model
AUTHOR: Alsheikhly Abdul-Razzak; Zweiri Jehad; Walmesley Alice J; Watson
Alastair J M; Christmas Stephen E (Reprint)
AUTHOR ADDRESS: Sch MedDept Immunol, Univ Liverpool, Daulby St, Liverpool,
Merseyside, L69 3GA, UK**UK
AUTHOR E-MAIL ADDRESS: sechris@liv.ac.uk
JOURNAL: Cancer Immunology Immunotherapy 53 (11): p946-954 November 2004
2004
MEDIUM: print
ISSN: 0340-7004
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

13/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0015127053 BIOSIS NO.: 200500034118
Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant
hematopoiesis
AUTHOR: Griswold Ian J; Shen Lei J; La Rosee Paul; Demehri Shadmehr;

Heinrich Michael C; Braziel Rita M; McGreevey Laura; Haley Andrea D;
Giese Neill; Druker Brian J; Deininger Michael W N (Reprint)
AUTHOR ADDRESS: Howard Hughes Med InstBMT Leukemia CtrInst Canc, Oregon
Hlth Sci Univ, 3181 SW Sam Jackson Pk Rd,L592, Portland, OR, 97239, USA**
USA
AUTHOR E-MAIL ADDRESS: deininge@ohsu.edu
JOURNAL: Blood 104 (9): p2912-2918 November 1, 2004 2004
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

13/3/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0015073146 BIOSIS NO.: 200400441065
Short-term Flt3L treatment effectively mobilizes functional macaque
dendritic cells
AUTHOR: Teleshova Natalia; Jones Jennifer; Kenney Jessica; Purcell Jeanette
; Bohm Rudolf; Gettie Agegnehu; Pope Melissa (Reprint)
AUTHOR ADDRESS: Ctr Biomed Res, Populat Council, 1230 York Ave, New York,
NY, 10021, USA**USA
AUTHOR E-MAIL ADDRESS: mpope@popcbr.rockefeller.edu
JOURNAL: Journal of Leukocyte Biology 75 (6): p1102-1110 June 2004 2004
MEDIUM: print
ISSN: 0741-5400 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

13/3/13 (Item 13 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014980415 BIOSIS NO.: 200400351204
Treatment of neonatal mice with Flt3 ligand leads to changes in dendritic
cell subpopulations associated with enhanced IL-12 and IFN-alpha
production
AUTHOR: Vollstedt Sabine; O'Keefe Meredith; Odermatt Bernhard; Beat Ryf;
Glanzmann Bettina; Riesen Matthias; Shortman Ken; Suter Mark (Reprint)
AUTHOR ADDRESS: Inst Virol, Univ Zurich, Winterthurerstr 266A, CH-8057,
Zurich, Switzerland**Switzerland
AUTHOR E-MAIL ADDRESS: msuter@vetvir.unizh.ch
JOURNAL: European Journal of Immunology 34 (7): p1849-1860 July 2004 2004
MEDIUM: print
ISSN: 0014-2980 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

13/3/14 (Item 14 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014877328 BIOSIS NO.: 200400246275
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for
the treatment of leukemias caused by oncogenic PTKs.

AUTHOR: Mohi M Golam (Reprint); Boulton Christina; Gu Ting-Lei; Sternberg David W; Neuberg Donna; Griffin James D; Gilliland D Gary; Neel Benjamin G
AUTHOR ADDRESS: Cancer Biology Program, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, New Research Building, Boston, MA, 02215, USA**USA
AUTHOR E-MAIL ADDRESS: gmohi@bidmc.harvard.edu
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 101 (9): p3130-3135 March 2, 2004 2004
MEDIUM: print
ISSN: 0027-8424 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

13/3/15 (Item 15 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014811839 BIOSIS NO.: 200400192596
Increased dendritic cell numbers impair protective immunity to intracellular bacteria despite augmenting antigen-specific CD8+ T lymphocyte responses.
AUTHOR: Alaniz Robert C; Sandall Sharsti; Thomas Elaine K; Wilson Christopher B (Reprint)
AUTHOR ADDRESS: Department of Immunology, University of Washington, 1959 NE Pacific Street, Box 357650, Seattle, WA, 98195, USA**USA
AUTHOR E-MAIL ADDRESS: cbwilson@u.washington.edu
JOURNAL: Journal of Immunology 172 (6): p3725-3735 March 15, 2004 2004
MEDIUM: print
ISSN: 0022-1767 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

13/3/16 (Item 16 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014781112 BIOSIS NO.: 200400147773
Analysis of activating FLT3 mutations in juvenile myelomonocytic leukemia.
AUTHOR: Gratias Eric J (Reprint); Liu Y Lucy; Castleberry Robert P (Reprint); Emanuel Peter D
AUTHOR ADDRESS: Pediatric Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA**USA
JOURNAL: Blood 102 (11): p662a November 16, 2003 2003
MEDIUM: print
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

13/3/17 (Item 17 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014781073 BIOSIS NO.: 200400147734

Combination of rapamycin with PTK inhibitors for the treatment of leukemias caused by oncogenic PTKs.

AUTHOR: Mohi M Golam (Reprint); Boulton Christina; Gu Ting-Lei; Sternberg David W; Neuberg Donna; Griffin James D; Gilliland D Gary; Neel Benjamin G (Reprint)

AUTHOR ADDRESS: Department of Medicine (Hematology-Oncology Division), Beth Israel Deaconess Medical Center, Boston, MA, USA**USA

JOURNAL: Blood 102 (11): p652a November 16, 2003 2003

MEDIUM: print

CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

13/3/18 (Item 18 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0014528704 BIOSIS NO.: 200300486361

Dendritic cell subsets in blood and lymphoid tissue of rhesus monkeys and their mobilization with Flt3 ligand.

AUTHOR: Coates P Toby H; Barratt-Boyes Simon M; Zhang Linyou; Donnenberg Vera S; O'Connell Peta J; Logar Alison J; Duncan F Jason; Murphey-Corb Michael; Donnenberg Albert D; Morelli Adrian E; Maliszewski Charles R; Thomson Angus W (Reprint)

AUTHOR ADDRESS: 200 Lothrop St, W1544 Biomedical Science Tower, Pittsburgh, PA, 15217, USA**USA

AUTHOR E-MAIL ADDRESS: thomsonaw@msx.upmc.edu

JOURNAL: Blood 102 (7): p2513-2521 October 1, 2003 2003

MEDIUM: print

ISSN: 0006-4971

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

13/3/19 (Item 19 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0014248789 BIOSIS NO.: 200300207508

A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.

AUTHOR: Sohal Jastinder; Phan Vernon T; Chan Philip V; Davis Elizabeth M; Patel Bhumi; Kelly Louise M; Abrams Tinya J; O'Farrell Anne Marie; Gilliland D Gary; Le Beau Michelle M; Kogan Scott C (Reprint)

AUTHOR ADDRESS: Comprehensive Cancer Center, University of California at San Francisco, 2340 Sutter St, Rm N-361, Box 0128, San Francisco, CA, 94143-0128, USA**USA

AUTHOR E-MAIL ADDRESS: skogan@cc.ucsf.edu

JOURNAL: Blood 101 (8): p3188-3197 April 15, 2003 2003

MEDIUM: print

ISSN: 0006-4971

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

13/3/20 (Item 20 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014205576 BIOSIS NO.: 200300164295
Flt3 ligand-treated neonatal mice have increased innate
immunity against intracellular pathogens and efficiently control
virus infections.
AUTHOR: Vollstedt Sabine; Franchini Marco; Hefti Hans P; Odermatt Bernhard;
O'Keefe Meredith; Alber Gottfried; Glanzmann Bettina; Riesen Matthias;
Ackermann Mathias; Suter Mark (Reprint)
AUTHOR ADDRESS: Institute of Virology, University of Zurich,
Winterhurerstr. 266a, 8057, Zurich, Switzerland**Switzerland
AUTHOR E-MAIL ADDRESS: msuter@vetvir.unizh.ch
JOURNAL: Journal of Experimental Medicine 197 (5): p575-584 March 3, 2003
2003
MEDIUM: print
ISSN: 0022-1007 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

13/3/21 (Item 21 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013627103 BIOSIS NO.: 200200220614
FLT3 internal tandem duplications and survival in adult acute myeloid
leukemia: Analysis of 188 intensively treated patients
AUTHOR: Froehling Stefan (Reprint); Breitruck Jochen (Reprint); Schlenk
Richard (Reprint); Kreitmeier Sylvia (Reprint); Tobis Karen (Reprint);
Doehner Hartmut (Reprint); Doehner Konstanze (Reprint)
AUTHOR ADDRESS: Internal Medicine III, University Hospital of Ulm, Ulm,
Germany**Germany
JOURNAL: Blood 98 (11 Part 1): p717a November 16, 2001 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of
Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

13/3/22 (Item 22 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013228816 BIOSIS NO.: 200100400655
Hematopoietic growth factors in patients receiving intensive chemotherapy
for malignant disorders: Studies of granulocyte-colony stimulating factor
(G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF),
interleukin-3 (IL-3) and Flt-3 ligand (Flt3L)
AUTHOR: Bruserud Oystein (Reprint); Foss Brynjar; Petersen Hein
AUTHOR ADDRESS: Department of Medicine, Haukeland University Hospital,
N-5021, Bergen, Norway**Norway
JOURNAL: European Cytokine Network 12 (2): p231-238 April-June, 2001 2001
MEDIUM: print
ISSN: 1148-5493

DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

13/3/23 (Item 23 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013003681 BIOSIS NO.: 200100175520
Flt3 ligand pretreatment promotes protective immunity to *Listeria*
monocytogenes
AUTHOR: Gregory Stephen H (Reprint); Sagnimeni Athanasia J; Zurowski Nancy
B; Thomson Angus W
AUTHOR ADDRESS: Department of Medicine, Rhode Island Hospital/Brown
University School of Medicine, 55 Claverick Street, 432 Pierre M.
Galletti Building, Providence, RI, 02903, USA**USA
JOURNAL: Cytokine 13 (4): p202-208 21 February, 2001 2001
MEDIUM: print
ISSN: 1043-4666
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

13/3/24 (Item 24 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0012543261 BIOSIS NO.: 200000261574
Polyomavirus-infected dendritic cells induce antiviral CD8+ T lymphocytes
AUTHOR: Drake Donald R III; Moser Janice M; Hadley Annette; Altman John D;
Maliszewski Charles; Butz Eric; Lukacher Aron E (Reprint)
AUTHOR ADDRESS: Department of Pathology, Emory University School of
Medicine, 1639 Pierce Dr., Woodruff Memorial Research Building, Atlanta,
GA, 30322, USA**USA
JOURNAL: Journal of Virology 74 (9): p4093-4101 May, 2000 2000
MEDIUM: print
ISSN: 0022-538X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

13/3/25 (Item 25 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0012268592 BIOSIS NO.: 199900528252
Cancer immunotherapy
AUTHOR: Zitvogel Laurence (Reprint); Faure Florence
AUTHOR ADDRESS: Departement de biologie clinique, Institut Gustave-Roussy,
39, rue Camille-Desmoulins, 94805, Villejuif Cedex, France**France
JOURNAL: M-S (Medecine Sciences) 15 (8-9): p939-949 Aug.-Sept., 1999 1999
MEDIUM: print
ISSN: 0767-0974
DOCUMENT TYPE: Article; Literature Review
RECORD TYPE: Abstract
LANGUAGE: French

13/3/26 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

13725254 EMBASE No: 2005375992

Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model

Ali S.; King G.D.; Curtin J.F.; Candolfi M.; Xiong W.; Liu C.; Puntel M.; Cheng Q.; Prieto J.; Ribas A.; Kupiec-Weglinski J.; Van Rooijen N.; Lassmann H.; Lowenstein P.R.; Castro M.G.

M.G. Castro, Gene Therapeutics Research Institute, Cedars-Sinai Medical Center, Davis Building, 8700 Beverly Boulevard, Los Angeles, CA 90048 United States

AUTHOR EMAIL: castromg@cshs.org

Cancer Research (CANCER RES.) (United States) 15 AUG 2005, 65/16 (7194-7204)

CODEN: CNREA ISSN: 0008-5472

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 61

13/3/27 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2006 Elsevier B.V. All rts. reserv.

13153006 EMBASE No: 2005217110

Hematopoietic stem cell-based gene therapy against HIV infection: Promises and caveats

van Griensven J.; De Clercq E.; Debyser Z.

Z. Debyser, Department of Molecular Virology and Gene Therapy, KULAK, KU Leuven, Kapucijnenvoer 33, B-3000 Leuven, Flanders Belgium

AUTHOR EMAIL: zeger.debyser@med.kuleuven.ac.be

AIDS Reviews (AIDS REV.) (Spain) 2005, 7/1 (44-55)

CODEN: ADRVF ISSN: 1139-6121

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 114

13/3/28 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2006 Elsevier B.V. All rts. reserv.

13004220 EMBASE No: 2005062746

Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): Opportunities and challenges

Sternberg D.W.; Licht J.D.

J.D. Licht, Division of Hematology/Oncology, Mount Sinai School of Medicine, Box 1079, 1 Gustave L Levy Race, New York, NY 10029 United States

AUTHOR EMAIL: jonathan.licht@mssm.edu

Current Opinion in Hematology (CURR. OPIN. HEMATOL.) (United States) 2005, 12/1 (7-13)

CODEN: COHEF ISSN: 1065-6251

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 70

13/3/29 (Item 4 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2006 Elsevier B.V. All rts. reserv.

12993672 EMBASE No: 2005051177
DNA vaccination against tumors
Prud'homme G.J.
G.J. Prud'homme, St. Michael's Hospital, 30 Bond St., Toronto, Ont. M5B
1W8 Canada
AUTHOR EMAIL: prudhommeg@smh.toronto.on.ca
Journal of Gene Medicine (J. GENE MED.) (United Kingdom) 2005, 7/1
(3-17)
CODEN: JGMEF ISSN: 1099-498X
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 160

13/3/30 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

12865894 EMBASE No: 2004458183
Immunotherapeutic strategies for hepatocellular carcinoma
Butterfield L.H.
AUTHOR EMAIL: butterfieldl@upmc.edu
Gastroenterology (GASTROENTEROLOGY) (United States) 2004, 127/SUPPL.
(S232-S241)
CODEN: GASTA ISSN: 0016-5085
PUBLISHER ITEM IDENTIFIER: S0016508504016178
DOCUMENT TYPE: Journal ; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 46

13/3/31 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

12531313 EMBASE No: 2004122541
Increased Dendritic Cell Numbers Impair Protective Immunity to
Intracellular Bacteria Despite Augmenting Antigen-Specific CD8SUP+ T
Lymphocyte Responses
Alaniz R.C.; Sandall S.; Thomas E.K.; Wilson C.B.
Dr. C.B. Wilson, Department of Immunology, University of Washington, Box
357650, 1959 NE Pacific Street, Seattle, WA 98195 United States
AUTHOR EMAIL: cbwilson@u.washington.edu
Journal of Immunology (J. IMMUNOL.) (United States) 15 MAR 2004,
172/6 (3725-3735)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 69

13/3/32 (Item 7 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

12329144 EMBASE No: 2003442451
Gene therapy for inborn and acquired immune deficiency disorders
Engel B.C.; Kohn D.B.
B.C. Engel, Mailstop # 62, Children's Hospital Los Angeles, 4650 Sunset
Blvd., Los Angeles, CA 90027 United States
AUTHOR EMAIL: bengel@chla.usc.edu

Acta Haematologica (ACTA HAEMATOL.) (Switzerland) 2003, 110/2-3
(60-70)
CODEN: ACHAA ISSN: 0001-5792
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 105

13/3/33 (Item 8 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

12222422 EMBASE No: 2003332561
The history, evolution, and clinical use of dendritic cell-based
immunization strategies in the therapy of brain tumors
Fecci P.E.; Mitchell D.A.; Archer G.E.; Morse M.A.; Lysterly H.K.; Bigner
D.D.; Sampson J.H.
J.H. Sampson, Division of Neurosurgery, Duke University, Medical Center,
Durham, NC 27710 United States
AUTHOR EMAIL: samps001@mc.duke.edu
Journal of Neuro-Oncology (J. NEURO-ONCOL.) (United States) 2003,
64/1-2 (161-176)
CODEN: JNODD ISSN: 0167-594X
DOCUMENT TYPE: Journal ; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 152

13/3/34 (Item 9 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

12051252 EMBASE No: 2003161013
Dendritic cells as a conduit to improve HIV vaccines
Pope M.
M. Pope, Center for Biomedical Research, Population Council, 1230 York
Avenue, New York, NY 10021 United States
AUTHOR EMAIL: mpope@popcbr.rockefeller.edu
Current Molecular Medicine (CURR. MOL. MED.) (Netherlands) 2003, 3/3
(229-242)
CODEN: CMMUB ISSN: 1566-5240
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 228

13/3/35 (Item 10 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

12006449 EMBASE No: 2003116660
Cancer vaccines
Singh V.; Kumar S.; Dewan R.; Zachariah S.; Khatri S.; Anand R.
V. Singh, Department of Medicine, Maulana Azad Medical College, New Delhi
India
Journal of Internal Medicine of India (J. INTERN. MED. INDIA) (India)
2002, 5/4 (196-202)
CODEN: JIMIF ISSN: 0972-1096
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 26

13/3/36 (Item 11 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

11989111 EMBASE No: 2003099665
Advances in immunotherapy for prostate cancer
Markiewicz M.A.; Kast W.M.
M.A. Markiewicz, Cancer Immunology Program, Cardinal Bernardin Cancer
Center, Loyola University Chicago, Maywood, IL 60153 United States
Advances in Cancer Research (ADV. CANCER RES.) (United States) 2003,
87/- (159-194)
CODEN: ACRSA ISSN: 0065-230X
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 153

13/3/37 (Item 12 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

10906052 EMBASE No: 2000393570
Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine
Pisarev V.M.; Parajuli P.; Mosley R.L.; Sublet J.; Kelsey L.; Sarin P.S.;
Zimmerman D.H.; Winship M.D.; Talmadge J.E.
J.E. Talmadge, Laboratory Transplantation Immunol., Department
Pathology/Microbiology, Nebraska Medical Center, Omaha, NE 68198-5660
United States
AUTHOR EMAIL: jtalmad@unmc.edu
International Journal of Immunopharmacology (INT. J. IMMUNOPHARMACOL.)
(United Kingdom) 2000, 22/11 (865-876)
CODEN: IJIMD ISSN: 0192-0561
PUBLISHER ITEM IDENTIFIER: S0192056100000485
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 56

13/3/38 (Item 13 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

10733038 EMBASE No: 2000142755
Polyomavirus-infected dendritic cells induce antiviral CD8sup + T
lymphocytes
Drake III D.R.; Moser J.M.; Hadley A.; Altman J.D.; Maliszewski C.; Butz
E.; Lukacher A.E.
A.E. Lukacher, Department of Pathology, Emory University School of
Medicine, Woodruff Memorial Research Building, 1639 Pierce Dr., Atlanta,
GA 30322 United States
AUTHOR EMAIL: alukach@emory.edu
Journal of Virology (J. VIROL.) (United States) 2000, 74/9 (4093-4101)
CODEN: JOVIA ISSN: 0022-538X
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 64

13/3/39 (Item 14 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

07411598 EMBASE No: 1998313000

Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: Implications for anti-cancer and anti-viral therapy

Shaw S.G.; Maung A.A.; Steptoe R.J.; Thomson A.W.; Vujanovic N.L.

Dr. N.L. Vujanovic, Univ. of Pittsburgh Cancer Institute, W1045

Biomedical Science Tower, 211 Lothrop St., Pittsburgh, PA 15213 United States

Journal of Immunology (J. IMMUNOL.) (United States) 15 SEP 1998, 161/6 (2817-2824)

CODEN: JOIMA ISSN: 0022-1767

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 45

13/3/40 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

15601586 PMID: 16155011

Genetics of myeloid malignancies: pathogenetic and clinical implications.

Frohling Stefan; Scholl Claudia; Gilliland D Gary; Levine Ross L

Brigham and Women's Hospital, Division of Hematology, Karp Family Research Building, 5th Floor, 1 Blackfan Cir, Boston, MA 02115, USA. sfrohling@rics.bwh.harvard.edu

Journal of clinical oncology - official journal of the American Society of Clinical Oncology (United States) Sep 10 2005, 23 (26) p6285-95,

ISSN 0732-183X--Print Journal Code: 8309333

Publishing Model Print

Document type: Journal Article; Review

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

13/3/41 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

145025892 CA: 145(2)25892t CONFERENCE PROCEEDING

Effect of FLT3-ligand treatment on hematological and immunological on hematological and immunological responses in SHIV infected rhesus monkeys: a pilot study

AUTHOR(S): Nehete, P.; Nehete, B.; Buchl, S.; Sastry, K. J.

LOCATION: Department of Veterinary Sciences, MD Anderson Cancer Center, The University of Texas, Bastrop, TX, USA

JOURNAL: Immunol. 2004, (12th Int. Congr. Immunol. 4th Annu. Conf. FOCIS) (Immunology 2004, (12th International Congress of Immunology and 4th Annual Conference of FOCIS), Montreal, QC, Canada, July 18-23, 2004)

DATE: 2004 PAGES: E718C6219/1-E718C6219/6 CODEN: 69HJYL MEDIA TYPE: computer optical disk LANGUAGE: English PUBLISHER: Monduzzi Editore, Bologna, Italy ISBN: 88-7587-070-5

13/3/42 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

144205750 CA: 144(12)205750h PATENT

Combined thymidine kinase-Flt3L gene therapy for the treatment of

macroscopic gliomas

INVENTOR(AUTHOR): Lowenstein, Pedro; Castro, Maria

LOCATION: USA

ASSIGNEE: Cedars-Sinai Medical Center

PATENT: PCT International ; WO 200620949 A2 DATE: 20060223

APPLICATION: WO 2005US28906 (20050812) *US 2004PV601100 (20040812)

PAGES: 32 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0048/00 A I F B 20060101 H US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

13/3/43 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

143025055 CA: 143(2)25055f PATENT

Adjuvants of immune response

INVENTOR(AUTHOR): Barouch, Dan H.; Sumida, Shawn M.; Letvin, Norman L.

LOCATION: USA

ASSIGNEE: Beth Israel Deaconess Medical Center

PATENT: PCT International ; WO 200552119 A2 DATE: 20050609

APPLICATION: WO 2004US38865 (20041119) *US 2003PV523380 (20031119)

PAGES: 78 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C12N-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

13/3/44 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

142423814 CA: 142(23)423814g PATENT

Combination therapy for cancer and viral infections

INVENTOR(AUTHOR): Moller, Niels Peter Hundahl; Skak, Kresten; Mueller, Jorn Roland

LOCATION: Den.

ASSIGNEE: Novo Nordisk A/S

PATENT: PCT International ; WO 200537306 A1 DATE: 20050428

APPLICATION: WO 2004DK683 (20041008) *DK 20031529 (20031017) *US 2003PV513422 (20031022) *DK 2004707 (20040504) *US 2004PV569566 (20040510)

PAGES: 60 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-038/20A; A61K-047/48B; A61P-035/00B; A61P-031/12B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

13/3/45 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

142333653 CA: 142(18)333653z JOURNAL
Pathogenesis and treatment of MLL-associated leukemia
AUTHOR(S): Hayashi, Yasuhide
LOCATION: Gunma Children's Medical Center, Gunma-ken, Japan, 377-8577
JOURNAL: Ketsueki, Shuyoka (Ketsueki, Shuyoka) DATE: 2004 VOLUME: 49
NUMBER: 1 PAGES: 11-19 CODEN: KETSBI ISSN: 0915-8529 LANGUAGE:
Japanese PUBLISHER: Kagaku Hyoronsha

13/3/46 (Item 6 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

142275041 CA: 142(15)275041k PATENT
Targeted particles comprising extracellular domain of FLT3L and cytoplasmic domain of HIV gp41 for treating autoimmune diseases
INVENTOR(AUTHOR): Weiner, David B.; Muthumani, Karuppiiah; Zhang, Donghui; Ramanathan, Mathura P.
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20050054104 A1 DATE: 20050310
APPLICATION: US 2004478896 (20040830) *US 2001PV293683 (20010525) *WO 2002US16681 (20020528)
PAGES: 23 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435456000; C12N-015/861A

13/3/47 (Item 7 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

142005477 CA: 142(1)5477w PATENT
Recombinant virus expressing an intact anti-tumor antibody containing human immunoglobulin constant regions and the therapeutic use thereof
INVENTOR(AUTHOR): Qian, Qijun; Yang, Qin
LOCATION: Peop. Rep. China,
ASSIGNEE: Sino-Gene Biotechnology Ltd.
PATENT: PCT International ; WO 2004101777 A1 DATE: 20041125
APPLICATION: WO 2004CN430 (20040429) *CN 2003116733 (20030430)
PAGES: 50 pp. CODEN: PIXXD2 LANGUAGE: Chinese
PATENT CLASSIFICATIONS:
CLASS: C12N-007/01A; C12N-015/13B; C12N-015/86B; C12N-015/861B; C12N-015/63B; C12N-015/24B; C12N-015/20B; C12N-015/27B; C12N-015/28B; A61K-035/76B; A61K-039/44B; A61P-035/00B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

13/3/48 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

140302117 CA: 140(19)302117g JOURNAL
Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion
AUTHOR(S): Sevilla, Noemi; McGavern, Dorian B.; Teng, Chao; Kunz, Stefan; Oldstone, Michael B. A.
LOCATION: Division of Virology, Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA, USA
JOURNAL: J. Clin. Invest. (Journal of Clinical Investigation) DATE: 2004
VOLUME: 113 NUMBER: 5 PAGES: 737-745 CODEN: JCINAO ISSN: 0021-9738
LANGUAGE: English PUBLISHER: American Society for Clinical Investigation

13/3/49 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

140247501 CA: 140(16)247501a DISSERTATION
Prevention of development of autoimmune thyroiditis through cytokine modulation using GM-CSF and Flt3-L
AUTHOR(S): Dogan, Rukiye E.
LOCATION: Health Sciences Center, Univ. of Illinois, Chicago, IL, USA
DATE: 2002 PAGES: 111 pp. CODEN: DABBBA LANGUAGE: English CITATION: Diss. Abstr. Int., B 2003, 63(12), 5749 AVAIL: UMI, Order No. DA3074213

13/3/50 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

138367598 CA: 138(24)367598t PATENT
Topical use of cytokines and chemokines for the treatment of viral or mycotic skin diseases or tumoral diseases
INVENTOR(AUTHOR): Nieland, John; Rehfuess, Christoph
LOCATION: Germany,
ASSIGNEE: Medigene Aktiengesellschaft
PATENT: PCT International ; WO 200339444 A2 DATE: 20030515
APPLICATION: WO 2002EP12438 (20021107) *DE 10154579 (20011107)
PAGES: 34 pp. CODEN: PIXXD2 LANGUAGE: German
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE

; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;
EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG;
CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

13/3/51 (Item 11 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

138297665 CA: 138(20)297665m PATENT
Methods using Flt3 ligand for preventing or reversing asthma, and
compositions useful therefor
INVENTOR(AUTHOR): Devendra, K. Agrawal
LOCATION: USA
ASSIGNEE: Creighton University
PATENT: PCT International ; WO 200332728 A2 DATE: 20030424
APPLICATION: WO 2002US33562 (20021019) *US PV344880 (20011019)
PAGES: 47 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A01N-037/18A; A01N-043/04B; A01N-063/00B; A61K-031/70B;
A61K-038/00B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS
; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE;
ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI;
CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

13/3/52 (Item 12 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

138132148 CA: 138(10)132148g PATENT
Recombinant viruses efficiently expressing angiogenesis inhibitory
protein and specifically replicating in tumors, and use thereof in cancer
therapy
INVENTOR(AUTHOR): Qian, Qijun; Che, Xiaoyan; Shan, Shuntong; Wu, Mengchao
LOCATION: Peop. Rep. China,
PATENT: PCT International ; WO 200308567 A1 DATE: 20030130
APPLICATION: WO 2002CN352 (20020524) *CN 2001113003 (20010525)
PAGES: 40 pp. CODEN: PIXXD2 LANGUAGE: Chinese
PATENT CLASSIFICATIONS:
CLASS: C12N-007/01A; C12N-015/12B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW;
AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW
; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;
GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG

13/3/53 (Item 13 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

137089115 CA: 137(7)89115j JOURNAL

Fibronectin fragment CH-296 inhibits apoptosis and enhances ex vivo gene transfer by murine retrovirus and human lentivirus vectors independent of viral tropism in nonhuman primate CD34+ cells

AUTHOR(S): Donahue, Robert E.; Sorrentino, Brian P.; Hawley, Robert G.; An, Dong Sung; Chen, Irvin S. Y.; Wersto, Robert P.

LOCATION: Hematology Branch, National Heart, Lung, Institute, National Institutes of Health, Bethesda, MD, 21892, USA

JOURNAL: Mol. Ther. (Molecular Therapy) DATE: 2001 VOLUME: 3 NUMBER: 3

PAGES: 359-367 CODEN: MTOHCK ISSN: 1525-0016 LANGUAGE: English

PUBLISHER: Academic Press

13/3/54 (Item 14 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

137045654 CA: 137(4)45654e JOURNAL

Intramuscular co-injection of naked DNA encoding HBV core antigen and Flt3 ligand suppresses anti-HBc antibody response

AUTHOR(S): Kwon, Taeg Kyu; Park, Jong-Wook

LOCATION: School of Medicine, Department of Immunology, Keimyung University, Jung-Gu, Taegu, 700-712, S. Korea

JOURNAL: Immunol. Lett. (Immunology Letters) DATE: 2002 VOLUME: 81

NUMBER: 3 PAGES: 229-234 CODEN: IMLED6 ISSN: 0165-2478

PUBLISHER ITEM IDENTIFIER: 0165-2478(02)00039-1 LANGUAGE: English

PUBLISHER: Elsevier Science Ireland Ltd.

13/3/55 (Item 15 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

135032660 CA: 135(3)32660n JOURNAL

Reduced herpes simplex virus type 1 latency in Flt-3 ligand-treated mice is associated with enhanced numbers of natural killer and dendritic cells

AUTHOR(S): Smith, J. R.; Thackray, A. M.; Bujdoso, R.

LOCATION: Centre for Veterinary Science, Department of Clinical Veterinary Medicine, University of Cambridge, Cambridge, UK, CB3 0ES

JOURNAL: Immunology DATE: 2001 VOLUME: 102 NUMBER: 3 PAGES: 352-358

CODEN: IMMUAM ISSN: 0019-2805 LANGUAGE: English PUBLISHER: Blackwell Science Ltd.

?

29sep06 08:26:57 User208760 Session D2789.1
\$0.39 0.111 DialUnits File1
\$0.39 Estimated cost File1
\$0.39 Estimated cost this search
\$0.39 Estimated total session cost 0.111 DialUnits

File 410:Dialog Comm.-of-Interest Newsl/Jul (c) 2006 Dialog

Set	Items	Description

? set hi ;set hi		
HIGHLIGHT set on as ''		
HIGHLIGHT set on as ''		
? begin 5,73,155,399		
29sep06 08:27:05 User208760 Session D2789.2		
	\$0.00	0.100 DialUnits File410
	\$0.00	Estimated cost File410
	\$0.03	TELNET
	\$0.03	Estimated cost this search
	\$0.42	Estimated total session cost 0.211 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2006/Sep W4
(c) 2006 The Thomson Corporation

File 73:EMBASE 1974-2006/Sep 29
(c) 2006 Elsevier B.V.

File 155:MEDLINE(R) 1950-2006/Sep 28
(c) format only 2006 Dialog

File 399:CA SEARCH(R) 1967-2006/UD=14514
(c) 2006 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=.. See HELP NEWSIPCR.

Set	Items	Description

? e au=brasel k ?		

Ref	Items	Index-term
E1	25	AU=BRASEL JO ANNE
E2	43	AU=BRASEL K
E3	0	*AU=BRASEL K ?
E4	9	AU=BRASEL K A
E5	2	AU=BRASEL K E
E6	20	AU=BRASEL K J
E7	32	AU=BRASEL K.
E8	2	AU=BRASEL K.A.
E9	1	AU=BRASEL K.E.
E10	44	AU=BRASEL K.J.
E11	8	AU=BRASEL KAREN
E12	43	AU=BRASEL KAREN J

Enter P or PAGE for more

? p

Ref	Items	Index-term
E13	11	AU=BRASEL KEN
E14	21	AU=BRASEL KENNETH
E15	3	AU=BRASEL KENNETH A
E16	2	AU=BRASEL M
E17	1	AU=BRASEL N
E18	3	AU=BRASEL T
E19	11	AU=BRASEL T L

E20 1 AU=BRASEL T.
 E21 7 AU=BRASEL T.L.
 E22 3 AU=BRASEL TREVOR
 E23 4 AU=BRASEL TREVOR L
 E24 1 AU=BRASEL, CHRIS

Enter P or PAGE for more

? s e13-e15

11 AU=BRASEL KEN
 21 AU=BRASEL KENNETH
 3 AU=BRASEL KENNETH A
 S1 35 E13-E15

? e au=lyman s ?

Ref	Items	Index-term
E1	2	AU=LYMAN RONALD
E2	80	AU=LYMAN S
E3	0	*AU=LYMAN S ?
E4	1	AU=LYMAN S B
E5	1	AU=LYMAN S C
E6	206	AU=LYMAN S D
E7	1	AU=LYMAN S J
E8	10	AU=LYMAN S K
E9	3	AU=LYMAN S L
E10	4	AU=LYMAN S M
E11	2	AU=LYMAN S R
E12	1	AU=LYMAN S T

Enter P or PAGE for more

? s e6

S2 206 AU='LYMAN S D'

? e au=maraskovsky e ?

Ref	Items	Index-term
E1	1	AU=MARASKOSKY E
E2	67	AU=MARASKOVSKY E
E3	0	*AU=MARASKOVSKY E ?
E4	61	AU=MARASKOVSKY E.
E5	83	AU=MARASKOVSKY EUGENE
E6	7	AU=MARASKOVSKY, E.
E7	54	AU=MARASKOVSKY, EUGENE
E8	1	AU=MARASKOWSKY, EUGENE
E9	2	AU=MARASLI B
E10	1	AU=MARASLI B.
E11	1	AU=MARASLI BARSAM
E12	2	AU=MARASLI NALAN

Enter P or PAGE for more

? s e1-e8

1 AU=MARASKOSKY E
 67 AU=MARASKOVSKY E
 0 AU=MARASKOVSKY E ?
 61 AU=MARASKOVSKY E.
 83 AU=MARASKOVSKY EUGENE
 7 AU=MARASKOVSKY, E.
 54 AU=MARASKOVSKY, EUGENE
 1 AU=MARASKOWSKY, EUGENE
 S3 274 E1-E8

? e au=mckenna h ?

Ref	Items	Index-term
E1	7	AU=MCKENNA GREGORY J

E2	75	AU=MCKENNA H
E3	0	*AU=MCKENNA H ?
E4	4	AU=MCKENNA H E
E5	46	AU=MCKENNA H J
E6	36	AU=MCKENNA H P
E7	1	AU=MCKENNA H V
E8	2	AU=MCKENNA H W
E9	23	AU=MCKENNA H.
E10	1	AU=MCKENNA H.E.
E11	1	AU=MCKENNA H.F.
E12	20	AU=MCKENNA H.J.

Enter P or PAGE for more

? p

Ref	Items	Index-term
E13	6	AU=MCKENNA H.P.
E14	1	AU=MCKENNA H.W.
E15	7	AU=MCKENNA HILARY
E16	19	AU=MCKENNA HILARY J
E17	25	AU=MCKENNA HUGH
E18	11	AU=MCKENNA HUGH P
E19	2	AU=MCKENNA I
E20	9	AU=MCKENNA I M
E21	1	AU=MCKENNA I.
E22	8	AU=MCKENNA I.M.
E23	1	AU=MCKENNA ILDA
E24	2	AU=MCKENNA ILDA M

Enter P or PAGE for more

? s e15-e16

	7	AU=MCKENNA HILARY
	19	AU=MCKENNA HILARY J
S4	26	E15-E16

? se au=lynch david ?

>>>Character "=" in invalid position

? e au=lynch d ?

Ref	Items	Index-term
E1	3	AU=LYNCH CYNTHIA M
E2	169	AU=LYNCH D
E3	0	*AU=LYNCH D ?
E4	98	AU=LYNCH D A
E5	49	AU=LYNCH D A F
E6	3	AU=LYNCH D BRIAN
E7	76	AU=LYNCH D C
E8	5	AU=LYNCH D D
E9	21	AU=LYNCH D E
E10	63	AU=LYNCH D F
E11	12	AU=LYNCH D F JR
E12	7	AU=LYNCH D G

Enter P or PAGE for more

? p

Ref	Items	Index-term
E13	181	AU=LYNCH D H
E14	63	AU=LYNCH D J
E15	2	AU=LYNCH D K
E16	61	AU=LYNCH D L
E17	80	AU=LYNCH D M
E18	2	AU=LYNCH D N

E19 1 AU=LYNCH D O
E20 56 AU=LYNCH D P
E21 183 AU=LYNCH D R
E22 5 AU=LYNCH D T
E23 70 AU=LYNCH D V
E24 56 AU=LYNCH D W

Enter P or PAGE for more

? s el3
S5 181 AU='LYNCH D H'
? s (s1 or s2 or s3 or s4 or s5) and (flt?)
35 S1
206 S2
274 S3
26 S4
181 S5
15188 FLT?
S6 228 (S1 OR S2 OR S3 OR S4 OR S5) AND (FLT?)
? rd s6
S7 161 RD S6 (unique items)
? s s7 and (infect? or bacteri?)
Processing
161 S7
3735184 INFECT?
3758317 BACTERI?
S8 10 S7 AND (INFECT? OR BACTERI?)
? rd s8
S9 10 RD S8 (unique items)
? t s9/3/all

9/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014469285 BIOSIS NO.: 200300424129
Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: Differential regulation of function by specific classes of physiologic stimuli.
AUTHOR: Jefford Michael; Schnurr Max; Toy Tracey; Masterman Kelly-Anne; Shin Amanda; Beecroft Tina; Tai Tsin Yee; Shortman Ken; Shackleton Mark; Davis Ian D; Parente Phil; Luft Thomas; Chen Weisan; Cebon Jonathan; Maraskovsky Eugene (Reprint)
AUTHOR ADDRESS: Oncology Unit, Ludwig Institute, Austin and Repatriation Medical Centre, Studley Rd, Heidelberg, VIC, 3084, Australia**Australia
AUTHOR E-MAIL ADDRESS: eugene.maraskovsky@ludwig.edu.au
JOURNAL: Blood 102 (5): p1753-1763 September 1, 2003 2003
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013430208 BIOSIS NO.: 200200023719
Functional analysis of dendritic cells generated in vitro from blood monocytes and CD34+ progenitors and in vivo with Flt3 ligand
AUTHOR: Luft T (Reprint); Jefford M (Reprint); Hochrein H; Rizkalla M (Reprint); Masterman K-A (Reprint); Maliszewski C; Shortman K; Cebon J

(Reprint); Maraskovsky E (Reprint)
AUTHOR ADDRESS: Ludwig Institute for Cancer Research, Melbourne, VIC,
Australia**Australia
JOURNAL: Journal of Investigative Dermatology 117 (4): p1005 October, 2001
2001
MEDIUM: print
CONFERENCE/MEETING: 7th International Workshop on Langerhans Cells Stresa,
Italy September 07-09, 2001; 20010907
ISSN: 0022-202X
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

9/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0011994558 BIOSIS NO.: 199900254218
Endogenous FLT-3 ligand serum levels are associated with disease
stage in patients with myelodysplastic syndromes
AUTHOR: Zwierzina H (Reprint); Anderson J E; Rollinger-Holzinger I;
Torok-Storb B; Nuessler V; Lyman S D
AUTHOR ADDRESS: Universitaetsklinik fuer Innere Medizin, A-6020, Innsbruck,
Austria**Austria
JOURNAL: Leukemia (Basingstoke) 13 (4): p553-557 April, 1999 1999
MEDIUM: print
ISSN: 0887-6924
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0011799110 BIOSIS NO.: 199900058770
Prevention of peripheral tolerance by a dendritic cell growth factor:
Flt3 ligand as an adjuvant
AUTHOR: Pulendran Bali (Reprint); Smith J L; Jenkins M; Schoenborn M;
Maraskovsky E; Maliszewski C R
AUTHOR ADDRESS: Baylor Inst. Immunol. Res., 3434 Live Oak, Dallas, TX
75204, USA**USA
JOURNAL: Journal of Experimental Medicine 188 (11): p2075-2082 Dec. 7,
1998 1998
MEDIUM: print
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0010719218 BIOSIS NO.: 199799353278
Soluble and membrane bound isoforms of Flt3-ligand induce antitumor
immunity in vivo
AUTHOR: Chen K (Reprint); Braun S E; Lyman S D; Broxmeyer H E;
Cornetta K

AUTHOR ADDRESS: Indiana Univ. Med. Sch., Indianapolis, IN, USA**USA
JOURNAL: Blood 88 (10 SUPPL. 1 PART 1-2): p274A 1996 1996
CONFERENCE/MEETING: Thirty-eighth Annual Meeting of the American Society of Hematology Orlando, Florida, USA December 6-10, 1996; 19961206
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Citation
LANGUAGE: English

9/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0010685405 BIOSIS NO.: 199799319465
Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified
AUTHOR: Maraskovsky Eugene (Reprint); Brasel Ken; Teepe Mark; Roux Eileen R; Lyman Stewart D; Shortman Ken; McKenna Hilary J
AUTHOR ADDRESS: Immunex Corporation, 51 University St., Seattle, WA 98101, USA**USA
JOURNAL: Journal of Experimental Medicine 184 (5): p1953-1962 1996 1996
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/7 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

06704387 EMBASE No: 1996369336
Dramatic increase in the number of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified
Maraskovsky E. ; Brasel K.; Teepe M.; Roux E.R.; Lyman S.D.; Shortman K.; McKenna H.J.
Immunex Corporation, 51 University St., Seattle, WA 98101 United States
Journal of Experimental Medicine (J. EXP. MED.) (United States) 1996, 184/5 (1953-1962)
CODEN: JEMEA ISSN: 0022-1007
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

9/3/8 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

11487631 PMID: 9322867
Efficient retrovirus-mediated gene transfer of dendritic cells generated from CD34+ cord blood cells under serum-free conditions.
Bello-Fernandez C; Matyash M; Strobl H; Pickl W F; Majdic O; Lyman S D; Knapp W
Vienna International Research Cooperation Center at Novartis Forschungsinstitut, University of Vienna, Austria.
Human gene therapy (UNITED STATES) Sep 20 1997, 8 (14) p1651-8,
ISSN 1043-0342--Print Journal Code: 9008950
Publishing Model Print
Document type: Journal Article

Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

9/3/9 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

128139750 CA: 128(12)139750z PATENT
Method of activating dendritic cells
INVENTOR(AUTHOR): Maraskovsky, Eugene; Mckenna, Hilary R.
LOCATION: USA
ASSIGNEE: Immunex Corp.
PATENT: PCT International ; WO 9801538 A1 DATE: 19980115
APPLICATION: WO 97US11956 (19970709) *US 677762 (19960710) *US 763995
(19961212)
PAGES: 35 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-005/00A; C12N-015/63B; C12N-015/09B; A61K-048/00B
DESIGNATED COUNTRIES: AU; CA; IL; JP; KR; MX; NO; NZ
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;
MC; NL; PT; SE

9/3/10 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

126304920 CA: 126(23)304920y PATENT
Dendritic cell stimulatory factor
INVENTOR(AUTHOR): Brasel, Kenneth; Lyman, Stewart D.; Maraskovsky, Eugene
; Mckenna, Hilary R.; Lynch, David H.
LOCATION: USA
ASSIGNEE: Immunex Corporation
PATENT: PCT International ; WO 9712633 A1 DATE: 19970410
APPLICATION: WO 96US15990 (19961003) *US 539142 (19951004)
PAGES: 21 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-045/05A; A61K-039/12B; A61K-039/02B; A61K-039/00B;
A01N-001/02B; C12N-005/00B
DESIGNATED COUNTRIES: AL; AU; BB; BG; BR; CA; CN; CZ; EE; GE; HU; IL; IS;
JP; KP; KR; LK; LR; LS; LT; LV; MG; MK; MN; MX; NO; NZ; PL; RO; SG; SI; SK;
TR; TT; UA; UZ; VN; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FI;
FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML;
MR; NE; SN; TD; TG
? ds

Set	Items	Description
S1	35	E13-E15
S2	206	AU='LYMAN S D'
S3	274	E1-E8
S4	26	E15-E16
S5	181	AU='LYNCH D H'
S6	228	(S1 OR S2 OR S3 OR S4 OR S5) AND (FLT?)
S7	161	RD S6 (unique items)
S8	10	S7 AND (INFECT? OR BACTERI?)
S9	10	RD S8 (unique items)

? s (Flt3?) (20n) (treat? or therap? or prevent? or inhibit? or
suppress?) (10n) (infect?)
Processing

Processing
Processing

	7614	FLT3?
	7690865	TREAT?
	7265769	THERAP?
	2524532	PREVENT?
	4650601	INHIBIT?
	968435	SUPPRESS?
	3735184	INFECT?
S10	62	(FLT3?) (20N) (TREAT? OR THERAP? OR PREVENT? OR INHIBIT? OR SUPPRESS?) (10N) (INFECT?)
? rd s10		
S11	39	RD S10 (unique items)

t s11/3/all

11/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015837075 BIOSIS NO.: 200600182470

The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in a murine bone marrow transplantation model.

AUTHOR: Schessl Christina (Reprint); Rawat Vijay P S; Cusan Monica; Deshpande Aniruddha; Kohl Tobias M; Rosten Patricia M; Spiekermann Karsten; Humphries R Keith; Schnittger Susanne; Kern Wolfgang; Hiddemann Wolfgang; Quintanilla-Martinez Leticia; Bohlander Stefan K; Feuring-Buske Michaela; Buske Christian

AUTHOR ADDRESS: Univ Munich, Dept Med 3, Klinikum Grosshadern, GSF, Clin Cooper Grp Leukemia, Munich, Germany**Germany

JOURNAL: Blood 106 (11, Part 1): p34A NOV 16 2005 2005

CONFERENCE/MEETING: 47th Annual Meeting of the American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005; 20051210

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

11/3/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015662596 BIOSIS NO.: 200600007991

Fms-like tyrosine kinase 3-based immunoprophylaxis against infection is improved by adjuvant treatment with anti-interleukin-10 antibody

AUTHOR: Das Lopamudra; DeVecchio Jennifer; Heinzel Frederick P (Reprint)

AUTHOR ADDRESS: Case Western Reserve Univ, Ctr Global Hlth and Dis, 10900 Euclid Ave, Cleveland, OH 44106 USA**USA

AUTHOR E-MAIL ADDRESS: fxh10@case.edu

JOURNAL: Journal of Infectious Diseases 192 (4): p693-702 AUG 15 2005 2005

ISSN: 0022-1899

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

11/3/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015573520 BIOSIS NO.: 200510268020

Acceleration and enhancement of T-cell recovery and immune competence by Flt3-ligand (Flt3L) following BMT with low numbers of progenitor cells in immune deficient mice.

AUTHOR: Wils Evert-Jan (Reprint); Broers Annoek E C; Verjans Georges M G M; Niesters Bert; Osterhaus Albert D M E; Spits Hergen; Lowenberg Bob; Wagemaker Gerard; Braakman Erik; Cornelissen Jan J

AUTHOR ADDRESS: Erasmus Univ, Ctr Med, Rotterdam, Netherlands**Netherlands

JOURNAL: Blood 104 (11, Part 1): p17A NOV 16 2004 2004

CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

11/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0015234870 BIOSIS NO.: 200500141935
Enhancement of dendritic cell production by Fms-like tyrosine kinase-3
ligand increases the resistance of mice to a burn wound infection
AUTHOR: Toliver-Kinsky Tracy E (Reprint); Cui Weihua; Murphey Erle D; Lin
Chengyie; Sherwood Edward R
AUTHOR ADDRESS: Med BranchDept Anesthesiol, Univ Texas, 301 Univ Blvd,
Galveston, TX, 77555, USA**USA
AUTHOR E-MAIL ADDRESS: ttoliver@utmb.edu
JOURNAL: Journal of Immunology 174 (1): p404-410 January 1, 2005 2005
MEDIUM: print
ISSN: 0022-1767 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0015073146 BIOSIS NO.: 200400441065
Short-term Flt3L treatment effectively mobilizes functional macaque
dendritic cells
AUTHOR: Teleshova Natalia; Jones Jennifer; Kenney Jessica; Purcell Jeanette
; Bohm Rudolf; Gettie Agegnehu; Pope Melissa (Reprint)
AUTHOR ADDRESS: Ctr Biomed Res, Populat Council, 1230 York Ave, New York,
NY, 10021, USA**USA
AUTHOR E-MAIL ADDRESS: mpope@popcbr.rockefeller.edu
JOURNAL: Journal of Leukocyte Biology 75 (6): p1102-1110 June 2004 2004
MEDIUM: print
ISSN: 0741-5400 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014811839 BIOSIS NO.: 200400192596
Increased dendritic cell numbers impair protective immunity to
intracellular bacteria despite augmenting antigen-specific CD8+ T
lymphocyte responses.
AUTHOR: Alaniz Robert C; Sandall Sharsti; Thomas Elaine K; Wilson
Christopher B (Reprint)
AUTHOR ADDRESS: Department of Immunology, University of Washington, 1959 NE
Pacific Street, Box 357650, Seattle, WA, 98195, USA**USA
AUTHOR E-MAIL ADDRESS: cbwilson@u.washington.edu
JOURNAL: Journal of Immunology 172 (6): p3725-3735 March 15, 2004 2004
MEDIUM: print
ISSN: 0022-1767 (ISSN print)

DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014801867 BIOSIS NO.: 200400172624
Pim-1 is upregulated in constitutively activating FLT3 mutants and is one of components of the cell survival.
AUTHOR: Kim Kyu-Tae (Reprint); Baird Kristin; Ahn Joon-Young (Reprint); Meltzer Paul; Small Donald (Reprint)
AUTHOR ADDRESS: Sydney Kimmel Comprehensive Cancer Centre, Johns Hopkins Medical Institution, Baltimore, MD, USA**USA
JOURNAL: Blood 102 (11): p172a November 16, 2003 2003
MEDIUM: print
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

11/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014746178 BIOSIS NO.: 200400116935
Adenovirus-mediated Flt3L-gene therapy protects against colon cancer metastasis in a BALB/c mouse model.
AUTHOR: Riediger Carina (Reprint); Wingeuder Gerhard; Knolle Percy; Stremmel Wolfgang (Reprint); Encke Jens (Reprint)
AUTHOR ADDRESS: Dept. of Internal Medicine IV, Heidelberg, Germany**Germany
JOURNAL: Hepatology 38 (4 Suppl. 1): p405A October 2003 2003
MEDIUM: print
CONFERENCE/MEETING: 54th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, USA October 24-28, 2003; 20031024
SPONSOR: American Association for the Study of Liver Diseases
ISSN: 0270-9139 (ISSN print)
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

11/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014528704 BIOSIS NO.: 200300486361
Dendritic cell subsets in blood and lymphoid tissue of rhesus monkeys and their mobilization with Flt3 ligand.
AUTHOR: Coates P Toby H; Barratt-Boyes Simon M; Zhang Linyou; Donnenberg Vera S; O'Connell Peta J; Logar Alison J; Duncan F Jason; Murphey-Corb Michael; Donnenberg Albert D; Morelli Adrian E; Maliszewski Charles R; Thomson Angus W (Reprint)
AUTHOR ADDRESS: 200 Lothrop St, W1544 Biomedical Science Tower, Pittsburgh, PA, 15217, USA**USA
AUTHOR E-MAIL ADDRESS: thomsonaw@msx.upmc.edu

JOURNAL: Blood 102 (7): p2513-2521 October 1, 2003 2003
MEDIUM: print
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014397571 BIOSIS NO.: 200300356290
Potential Activation of Pre-Leukemic Events by Retroviral Over-Expression
of HoxA9 in Human CD34+ Cells.
AUTHOR: Neering Sarah J (Reprint); Guzman Monica L; Echlin-Bell Deborah R;
Swiderski Carol F; Vanin Elio F; Sauvageau Guy; Jordan Craig T
AUTHOR ADDRESS: Hematology/Oncology, Markey Cancer Center, Lexington, KY,
USA**USA
JOURNAL: Blood 100 (11): pAbstract No. 238 November 16, 2002 2002
MEDIUM: print
CONFERENCE/MEETING: 44th Annual Meeting of the American Society of
Hematology Philadelphia, PA, USA December 06-10, 2002; 20021206
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

11/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014383936 BIOSIS NO.: 200300340679
Stimulation of hematopoiesis by the Fms-like tyrosine kinase 3 ligand
restores bacterial induction of Th1 cytokines in thermally injured mice.
AUTHOR: Toliver-Kinsky Tracy E (Reprint); Lin Cheng Y; Herndon David N;
Sherwood Edward R
AUTHOR ADDRESS: Department of Anesthesiology, University of Texas Medical
Branch, 301 University Boulevard, Galveston, TX, 77555-0591, USA**USA
AUTHOR E-MAIL ADDRESS: ttoliver@utmb.edu
JOURNAL: Infection and Immunity 71 (6): p3058-3067 June 2003 2003
MEDIUM: print
ISSN: 0019-9567 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014205576 BIOSIS NO.: 200300164295
Flt3 ligand-treated neonatal mice have increased innate
immunity against intracellular pathogens and efficiently control virus
infections
AUTHOR: Vollstedt Sabine; Franchini Marco; Hefti Hans P; Odermatt Bernhard;
O'Keefe Meredith; Alber Gottfried; Glanzmann Bettina; Riesen Matthias;
Ackermann Mathias; Suter Mark (Reprint)
AUTHOR ADDRESS: Institute of Virology, University of Zurich,

Winterhurerstr. 266a, 8057, Zurich, Switzerland**Switzerland
AUTHOR E-MAIL ADDRESS: msuter@vetvir.unizh.ch
JOURNAL: Journal of Experimental Medicine 197 (5): p575-584 March 3, 2003
2003
MEDIUM: print
ISSN: 0022-1007 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/13 (Item 13 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013776931 BIOSIS NO.: 200200370442
Flt3L induces antileishmanial immunity independent of eventual CD4+ Th cell phenotype
AUTHOR: Das Lopamudra (Reprint); Heinzl Frederick P (Reprint)
AUTHOR ADDRESS: Geographic Medicine, Case Western Reserve University, 2109 Adelbert Rd, Cleveland, OH, 44106-4983, USA**USA
JOURNAL: FASEB Journal 16 (5): pA1037 March 22, 2002 2002
MEDIUM: print
CONFERENCE/MEETING: Annual Meeting of Professional Research Scientists on Experimental Biology New Orleans, Louisiana, USA April 20-24, 2002; 20020420
ISSN: 0892-6638
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

11/3/14 (Item 14 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013228816 BIOSIS NO.: 200100400655
Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: Studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L)
AUTHOR: Bruserud Oystein (Reprint); Foss Brynjar; Petersen Hein
AUTHOR ADDRESS: Department of Medicine, Haukeland University Hospital, N-5021, Bergen, Norway**Norway
JOURNAL: European Cytokine Network 12 (2): p231-238 April-June, 2001 2001
MEDIUM: print
ISSN: 1148-5493
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/15 (Item 15 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013003681 BIOSIS NO.: 200100175520
Flt3 ligand pretreatment promotes protective immunity to Listeria monocytogenes
AUTHOR: Gregory Stephen H (Reprint); Sagnimeni Athanasia J; Zurowski Nancy B; Thomson Angus W
AUTHOR ADDRESS: Department of Medicine, Rhode Island Hospital/Brown

University School of Medicine, 55 Claverick Street, 432 Pierre M.
Galletti Building, Providence, RI, 02903, USA**USA
JOURNAL: Cytokine 13 (4): p202-208 21 February, 2001 2001
MEDIUM: print
ISSN: 1043-4666
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/16 (Item 16 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0012969863 BIOSIS NO.: 200100141702
Pretreatment with recombinant Flt3 ligand partially protects against
progressive cutaneous leishmaniasis in susceptible BALB/c mice
AUTHOR: Kremer Inger B; Gould Meetha P; Cooper Kevin D; Heinzl Frederick P
(Reprint)
AUTHOR ADDRESS: Division of Geographic Medicine, Case Western Reserve
University School of Medicine, W-137, Cleveland, OH, 44106-4983, USA**USA
JOURNAL: Infection and Immunity 69 (2): p673-680 February, 2001 2001
MEDIUM: print
ISSN: 0019-9567
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/17 (Item 17 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0012802298 BIOSIS NO.: 200000520611
Effect of CD40 ligand and other immunomodulators on Pneumocystis carinii
infection in rat model
AUTHOR: Oz Helieh S (Reprint); Hughes Walter T; Rehlg Jerold E; Thomas
Elaine K
AUTHOR ADDRESS: Department of Internal Medicine, University of Kentucky
Medical Center, Lexington, KY, 40536, USA**USA
JOURNAL: Microbial Pathogenesis 29 (3): p187-190 September, 2000 2000
MEDIUM: print
ISSN: 0882-4010
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/18 (Item 18 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0012543261 BIOSIS NO.: 200000261574
Polyomavirus-infected dendritic cells induce antiviral CD8+ T lymphocytes
AUTHOR: Drake Donald R III; Moser Janice M; Hadley Annette; Altman John D;
Maliszewski Charles; Butz Eric; Lukacher Aron E (Reprint)
AUTHOR ADDRESS: Department of Pathology, Emory University School of
Medicine, 1639 Pierce Dr., Woodruff Memorial Research Building, Atlanta,
GA, 30322, USA**USA
JOURNAL: Journal of Virology 74 (9): p4093-4101 May, 2000 2000
MEDIUM: print
ISSN: 0022-538X

DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

11/3/19 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

12531313 EMBASE No: 2004122541
Increased Dendritic Cell Numbers Impair Protective Immunity to
Intracellular Bacteria Despite Augmenting Antigen-Specific CD8SUP+ T
Lymphocyte Responses
Alaniz R.C.; Sandall S.; Thomas E.K.; Wilson C.B.
Dr. C.B. Wilson, Department of Immunology, University of Washington, Box
357650, 1959 NE Pacific Street, Seattle, WA 98195 United States
AUTHOR EMAIL: cbwilson@u.washington.edu
Journal of Immunology (J. IMMUNOL.) (United States) 15 MAR 2004,
172/6 (3725-3735)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 69

11/3/20 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

10733038 EMBASE No: 2000142755
Polyomavirus-infected dendritic cells induce antiviral CD8sup + T
lymphocytes
Drake III D.R.; Moser J.M.; Hadley A.; Altman J.D.; Maliszewski C.; Butz
E.; Lukacher A.E.
A.E. Lukacher, Department of Pathology, Emory University School of
Medicine, Woodruff Memorial Research Building, 1639 Pierce Dr., Atlanta,
GA 30322 United States
AUTHOR EMAIL: alukach@emory.edu
Journal of Virology (J. VIROL.) (United States) 2000, 74/9 (4093-4101)
CODEN: JOVIA ISSN: 0022-538X
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 64

11/3/21 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

07411598 EMBASE No: 1998313000
Expansion of functional NK cells in multiple tissue compartments of mice
treated with Flt3-ligand: Implications for anti-cancer and anti-viral
therapy
Shaw S.G.; Maung A.A.; Steptoe R.J.; Thomson A.W.; Vujanovic N.L.
Dr. N.L. Vujanovic, Univ. of Pittsburgh Cancer Institute, W1045
Biomedical Science Tower, 211 Lothrop St., Pittsburgh, PA 15213 United
States
Journal of Immunology (J. IMMUNOL.) (United States) 15 SEP 1998, 161/6
(2817-2824)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 45

11/3/22 (Item 1 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

13844694 PMID: 12126551
[Gene transfer of murine Flt3 ligand mediated by adenoviral vector efficiently induces growth inhibition of murine liver cancer]
Yang Qing; Yang Guangshun; Wei Lixin; Jia Fengqi; Wu Mengchao; Guo Yajun
Tumor Immunology and Biotherapy Center, Eastern Institute of Hepatobiliary Surgery, Second Military Medical University, Shanghai, China.
Zhonghua yi xue za zhi (China) Jun 10 2002, 82 (11) p775-9, ISSN 0376-2491--Print Journal Code: 7511141
Publishing Model Print
Document type: Journal Article ; English Abstract
Languages: CHINESE
Main Citation Owner: NLM
Record type: MEDLINE; Completed

11/3/23 (Item 1 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

145077690 CA: 145(5)77690v PATENT
Preparation of extracellular domain of dog Flt3 and its use for treatment dog diseases
INVENTOR(AUTHOR): Nishikawa, Yoshifumi; Okano, Fumiyoshi
LOCATION: Japan,
ASSIGNEE: Toray Industries, Inc.
PATENT: Japan Kokai Tokkyo Koho ; JP 2006166908 A2 DATE: 20060629
APPLICATION: JP 2005332045 (20051116) *JP 2004335567 (20041119)
PAGES: 35 pp. CODEN: JKXXAF LANGUAGE: Japanese
PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

C12N-0015/09	A	I	F	B	20060101	20060602	H	JP
C07K-0014/47	A	I	L	B	20060101	20060602	H	JP
C12N-0001/15	A	I	L	B	20060101	20060602	H	JP
C12N-0001/19	A	I	L	B	20060101	20060602	H	JP
C12N-0001/21	A	I	L	B	20060101	20060602	H	JP
C12N-0005/10	A	I	L	B	20060101	20060602	H	JP
C12N-0007/00	A	I	L	B	20060101	20060602	H	JP
C12P-0021/02	A	I	L	B	20060101	20060602	H	JP
C07K-0016/18	A	I	L	B	20060101	20060602	H	JP
A61K-0045/00	A	I	L	B	20060101	20060602	H	JP
A61K-0038/00	A	I	L	B	20060101	20060602	H	JP
A61K-0035/14	A	I	L	B	20060101	20060602	H	JP
A61P-0031/12	A	I	L	B	20060101	20060602	H	JP
A61P-0035/00	A	I	L	B	20060101	20060602	H	JP

11/3/24 (Item 2 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

145025892 CA: 145(2)25892t CONFERENCE PROCEEDING
Effect of FLT3-ligand treatment on hematological and immunological on hematological and immunological responses in SHIV infected rhesus monkeys: a pilot study
AUTHOR(S): Nehete, P.; Nehete, B.; Buchl, S.; Sastry, K. J.

LOCATION: Department of Veterinary Sciences, MD Anderson Cancer Center,
The University of Texas, Bastrop, TX, USA
JOURNAL: Immunol. 2004, (12th Int. Congr. Immunol. 4th Annu. Conf. FOCIS)
(Immunology 2004, (12th International Congress of Immunology and 4th
Annual Conference of FOCIS), Montreal, QC, Canada, July 18-23, 2004)
DATE: 2004 PAGES: E718C6219/1-E718C6219/6 CODEN: 69HJYL MEDIA TYPE:
computer optical disk LANGUAGE: English PUBLISHER: Monduzzi Editore,
Bologna, Italy ISBN: 88-7587-070-5

11/3/25 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

144487147 CA: 144(26)487147r PATENT
Yeast-based therapeutic vaccine vehicle for chronic hepatitis c infection
INVENTOR(AUTHOR): Duke, Richard C.; Franzusoff, Alex; Haller, Aurelia;
King, Thomas H.
LOCATION: USA
ASSIGNEE: Globeimmune, Inc.
PATENT: U.S. Pat. Appl. Publ. ; US 20060110755 A1 DATE: 20060525
APPLICATION: US 2005254252 (20051018) *US 2002PV434163 (20021216) *US
2003738646 (20031216) *US 2004PV620158 (20041018)
PAGES: 47 pp., Cont.-in-part of U.S. Ser. No. 738,646. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435006000
IPCR/8 + Level Value Position Status Version Action Source Office:
C12Q-0001/70 A I F B 20060101 20060525 H US
C12Q-0001/68 A I L B 20060101 20060525 H US

11/3/26 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

143025055 CA: 143(2)25055f PATENT
Adjuvants of immune response
INVENTOR(AUTHOR): Barouch, Dan H.; Sumida, Shawn M.; Letvin, Norman L.
LOCATION: USA
ASSIGNEE: Beth Israel Deaconess Medical Center
PATENT: PCT International ; WO 200552119 A2 DATE: 20050609
APPLICATION: WO 2004US38865 (20041119) *US 2003PV523380 (20031119)
PAGES: 78 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG

11/3/27 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

142423814 CA: 142(23)423814g PATENT
Combination therapy for cancer and viral infections
INVENTOR(AUTHOR): Moller, Niels Peter Hundahl; Skak, Kresten; Mueller,
Jorn Roland
LOCATION: Den.
ASSIGNEE: Novo Nordisk A/S
PATENT: PCT International ; WO 200537306 A1 DATE: 20050428
APPLICATION: WO 2004DK683 (20041008) *DK 20031529 (20031017) *US
2003PV513422 (20031022) *DK 2004707 (20040504) *US 2004PV569566 (20040510)
PAGES: 60 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-038/20A; A61K-047/48B; A61P-035/00B; A61P-031/12B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;
NE; SN; TD; TG

11/3/28 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

142054751 CA: 142(4)54751q PATENT
Alternative reading frame peptides as antigens for the prophylaxis and
treatment of cancer and infectious diseases
INVENTOR(AUTHOR): Graddis, Thomas; Laus, Reiner; Diegel, Michael;
Vidovic, Damis
LOCATION: USA
ASSIGNEE: Dendreon Corporation
PATENT: PCT International ; WO 2004111075 A2 DATE: 20041223
APPLICATION: WO 2004US6979 (20040305) *US 2003PV453131 (20030305)
PAGES: 147 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C07K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ
; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE;
BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL;
PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;
SN; TD; TG

11/3/29 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

141420433 CA: 141(26)420433a PATENT
Use of inhibitors of indoleamine-2,3-dioxygenase in combination with
other therapeutic modalities in the treatment of cancer and infection
INVENTOR(AUTHOR): Munn, David; Mellor, Andrew
LOCATION: USA
ASSIGNEE: Medical College of Georgia Research Institute, Inc.

PATENT: U.S. Pat. Appl. Publ. ; US 20040234623 A1 DATE: 20041125
APPLICATION: US 780797 (20040217) *US PV459489 (20030401) *US PV538647
(20040122)
PAGES: 42 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424649000; A61N-005/00A; A61K-031/704B; A61K-031/405B;
A61K-031/343B; A61K-031/381B

11/3/30 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

140373912 CA: 140(23)373912y PATENT
Immunostimulatory cytokine or encoding nucleic acid in combination with
antigen presenting cells for treating cancer, metastasis and infection
INVENTOR(AUTHOR): Lotze, Michael T.; Tahara, Hideaki
LOCATION: USA
ASSIGNEE: University of Pittsburgh of the Commonwealth System of Higher
Education
PATENT: PCT International ; WO 200434995 A2 DATE: 20040429
APPLICATION: WO 2003US32827 (20031015) *US PV418865 (20021015)
PAGES: 169 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE;
GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT;
LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PG; PH; PL; PT; RO;
RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN;
YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU DESIGNATED REGIONAL: GH; GM; KE
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

11/3/31 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

140302117 CA: 140(19)302117g JOURNAL
Viral targeting of hematopoietic progenitors and inhibition of DC
maturation as a dual strategy for immune subversion
AUTHOR(S): Sevilla, Noemi; McGavern, Dorian B.; Teng, Chao; Kunz, Stefan;
Oldstone, Michael B. A.
LOCATION: Division of Virology, Department of Neuropharmacology, The
Scripps Research Institute, La Jolla, CA, USA
JOURNAL: J. Clin. Invest. (Journal of Clinical Investigation) DATE: 2004
VOLUME: 113 NUMBER: 5 PAGES: 737-745 CODEN: JCINAO ISSN: 0021-9738
LANGUAGE: English PUBLISHER: American Society for Clinical Investigation

11/3/32 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

138168828 CA: 138(12)168828t PATENT
Cytokine receptor-activating agent and co-stimulatory molecule-activating
agent for prevention or treatment of cancer, inflammatory disorders or
infectious diseases
INVENTOR(AUTHOR): Chen, Shu-Hsia; Pan, Ping-Yan; Woo, Savio L. C.
LOCATION: USA

PATENT: U.S. Pat. Appl. Publ. ; US 20030035790 A1 DATE: 20030220
APPLICATION: US 165643 (20020607) *US PV115992 (19990115) *US 735296
(20000114)
PAGES: 81 pp., Cont.-in-part of U.S. Ser. No. 735,296. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424085200; A61K-048/00A; A61K-038/20B; A61K-039/395B

11/3/33 (Item 11 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

137368572 CA: 137(25)368572w PATENT
In situ injection of antigen-presenting cells with genetically enhanced
cytokine expression for treatment of tumors or infections
INVENTOR(AUTHOR): Tahara, Hideaki; Lotze, Michael T.; Nishioka, Yasuhiko
LOCATION: USA
ASSIGNEE: University of Pittsburgh of the Commonwealth System of Higher
Education
PATENT: United States ; US 6482405 B1 DATE: 20021119
APPLICATION: US 395836 (19990914) *US PV100048 (19980915)
PAGES: 16 pp. CODEN: USXXAM LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424093210; A61K-048/00A; A61K-031/00B; C12N-015/74B;
C12N-005/02B; C12N-005/00B

11/3/34 (Item 12 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

137168254 CA: 137(12)168254g PATENT
Superior molecular vaccine based on self-replicating RNA, suicidal DNA or
naked DNA vector, that links antigen with polypeptide that promotes
antigen presentation for treating cancer and infections
INVENTOR(AUTHOR): Wu, Tzyy-Choou; Hung, Chien-Fu
LOCATION: USA
ASSIGNEE: The Johns Hopkins University
PATENT: PCT International ; WO 200261113 A2 DATE: 20020808
APPLICATION: WO 2002US2598 (20020201) *US PV265334 (20010201)
PAGES: 127 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12Q-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW;
AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW
; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;
GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG

11/3/35 (Item 13 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

136368437 CA: 136(24)368437k PATENT
Agents inducing mobilization, maturation, and activation of dendritic
cells and T cell-enhancing factor are used for treating infection

INVENTOR(AUTHOR): Lynch, David H.; De Smedt, Thibaut N.; Maliszewski, Charles R.; Butz, Eric A.; Miller, Robert E.; Thomas, Elaine K.

LOCATION: USA

ASSIGNEE: Immunex Corporation

PATENT: PCT International ; WO 200236141 A2 DATE: 20020510

APPLICATION: WO 2001US44834 (20011030) *US PV245721 (20001102)

PAGES: 43 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-038/00A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

11/3/36 (Item 14 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

135194467 CA: 135(14)194467g PATENT

Adjuvant treatment by in vivo activation of dendritic cells using a mobilizing agent and activating agent plus antigen

INVENTOR(AUTHOR): Fong, Lawrence H.; Merad, Miriam; Engleman, Edgar G.

LOCATION: USA

ASSIGNEE: Board of Trustees of the Leland Stanford Junior University

PATENT: PCT International ; WO 200162275 A1 DATE: 20010830

APPLICATION: WO 2001US6022 (20010222) *US PV184810 (20000224)

PAGES: 22 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-038/19A; A61K-038/20B; A61K-039/00B; A61K-048/00B

DESIGNATED COUNTRIES: AU; CA; JP DESIGNATED REGIONAL: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR

11/3/37 (Item 15 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

132235909 CA: 132(18)235909m PATENT

In situ injection of antigen-presenting cells with genetically enhanced cytokine expression

INVENTOR(AUTHOR): Tahara, Hideaki; Lotze, Michael T.; Nishioka, Yasuhiko

LOCATION: USA

ASSIGNEE: University of Pittsburgh of the Commonwealth System of Higher Education

PATENT: PCT International ; WO 200015264 A1 DATE: 20000323

APPLICATION: WO 99US21097 (19990914) *US 100468 (19980915)

PAGES: 34 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-048/00A; A61K-039/00B

DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF;

CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

11/3/38 (Item 16 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

130195748 CA: 130(15)195748h PATENT
Recombinant porcine adenovirus vector
INVENTOR(AUTHOR): Johnson, Michael Anthony; Hammond, Jeffrey Michael
LOCATION: Australia
ASSIGNEE: Commonwealth Scientific and Industrial Research Organisation;
Pig Research Development Corporation Computer Associate House
PATENT: PCT International ; WO 9908706 A1 DATE: 19990225
APPLICATION: WO 98AU648 (19980814) *AU 978560 (19970814)
PAGES: 51 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/235A; C12N-015/63B; C12N-015/67B; C12N-015/86B
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;
CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; HR; HU; ID; IL; IS; JP; KE; KG;
KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL;
PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS
; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT;
LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD;
TG

11/3/39 (Item 17 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2006 American Chemical Society. All rts. reserv.

127201023 CA: 127(15)201023z PATENT
Stem cell transformation and differentiation to form recombinant
antigen-presenting dendritic cells that activate T cells and use for
treating cancer and infections
INVENTOR(AUTHOR): Hwu, Patrick; Reeves, Mark; Rosenberg, Steven A.
LOCATION: USA
ASSIGNEE: United States Dept. of Health and Human Services; Hwu, Patrick;
Reeves, Mark; Rosenberg, Steven A.
PATENT: PCT International ; WO 9729183 A2 DATE: 19970814
APPLICATION: WO 97US2063 (19970207) *US 11433 (19960208)
PAGES: 63 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-005/10A; C12N-005/08B; G01N-033/50B; A61K-048/00B
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;
CU; CZ; DE; DK; EE; ES; FI; GB; GE; HU; IL; IS; JP; KE; KG; KP; KR; KZ; LC;
LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD;
SE; SG; SI; SK; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; AM; AZ; BY; KG; KZ;
MD; RU; TJ; TM DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE
; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI;
CM; GA; GN; ML; MR; NE; SN; TD; TG

t s11/7/1-21,31

11/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0015837075 BIOSIS NO.: 200600182470

The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in a murine bone marrow transplantation model.

AUTHOR: Schessl Christina (Reprint); Rawat Vijay P S; Cusan Monica; Deshpande Aniruddha; Kohl Tobias M; Rosten Patricia M; Spiekermann Karsten; Humphries R Keith; Schnittger Susanne; Kern Wolfgang; Hiddemann Wolfgang; Quintanilla-Martinez Leticia; Bohlander Stefan K; Feuring-Buske Michaela; Buske Christian

AUTHOR ADDRESS: Univ Munich, Dept Med 3, Klinikum Grosshadern, GSF, Clin Cooper Grp Leukemia, Munich, Germany**Germany

JOURNAL: Blood 106 (11, Part 1): p34A NOV 16 2005 2005

CONFERENCE/MEETING: 47th Annual Meeting of the American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005; 20051210

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Experimental data have shown that two of the most frequent genetic alterations in AML, the AML1-ETO (A/E) fusion gene and the FLT3 length mutation (FLT3-LM) are both mostly insufficient on their own to induce leukemia. These findings support the model that collaboration of two classes of genetic alterations, altering proliferation or differentiation, is necessary for leukemogenesis. When we first analyzed 135 patients with A/E positive AML, additional mutations affecting signal transduction were found in 38% of all cases (FLT3-LM 10.3%, KIT 8.1% and NRAS 9.6%). In contrast, none of the patient with A/E positive leukemia had alterations associated with transcriptional regulation such as MLL PTD. To test the hypothesis that A/E collaborates with FLT3-LM in inducing acute leukemia, we transplanted mice with bone marrow (BM) cells retrovirally expressing A/E, FLT3-LM or both alterations. Mice transplanted with BM cells expressing A/E or FLT3-LM alone did not develop any disease. In contrast, mice (n=11) transplanted with BM cells expressing both alterations succumbed to an aggressive acute leukemia. Intriguingly, developing leukemias differed with regard to their phenotype with 7 animals developing AML and 4 animals developing ALL. Furthermore, the majority of AML cases showed simultaneous expression of lymphoid antigens as described in patients with A/E positive AML. The collaboration of A/E with FLT3-LM was depending on DNA binding activity of the fusion gene as the L148D point mutation in the Runx1 domain of the construct abrogated collaboration of A/E with the FLT3-LM in the CFU-S assay. Furthermore, inactivation of the kinase activity of the ***FLT3***-LM (FLT3-LM K672R mutant) resulted in the complete loss of collaboration with the A/E fusion. ***Treatment*** of cells co-infected with A/E and FLT3-LM with the kinase inhibitor PKC412 resulted in a 62% reduction of the CFU-S frequency. To further explore a possible contribution of retroviral insertional mutagenesis to the transformation process in this model, 10 retroviral integration sites were subcloned and sequenced from 4 leukemic mice: all 10 sites were unique with no indication of a common integration site associated with the leukemic transformation. Moreover, 5 sites were intergenic or not linked to known genes. The remaining sites were in introns in a 5' to 3' orientation most likely to lead to gene knockdown rather than activation. These data provide direct functional evidence for the oncogenic

collaboration between A/E with a class of activating mutations, recurrently found in patients with t(8;21), and add experimental data to the clinical observation which demonstrated a significant inferior treatment outcome in patients with AML1-ETO and additional Mutations of receptor tyrosine kinases.

11/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0015662596 BIOSIS NO.: 200600007991
Fms-like tyrosine kinase 3-based immunoprophylaxis against infection is improved by adjuvant treatment with anti-interleukin-10 antibody
AUTHOR: Das Lopamudra; DeVecchio Jennifer; Heinzl Frederick P (Reprint)
AUTHOR ADDRESS: Case Western Reserve Univ, Ctr Global Hlth and Dis, 10900 Euclid Ave, Cleveland, OH 44106 USA**USA
AUTHOR E-MAIL ADDRESS: fxhl0@case.edu
JOURNAL: Journal of Infectious Diseases 192 (4): p693-702 AUG 15 2005 2005
ISSN: 0022-1899
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Background. Fms-like tyrosine kinase 3 ligand (***Flt3L***) expands dendritic-cell populations in vivo and protects against microbial ***infection*** in healthy and immunocompromised hosts. Approaches for optimizing the protective effects of Flt3L in vivo are not well known.Methods. BALB/c mice were ***treated*** for 9 days with 10 mu g of recombinant (r) Flt3L with or without the addition of 250 mg of anti-interleukin (IL)-10 antibody on day 9. After Leishmania major infection, disease progression was determined by measuring cutaneous lesions. Production of IL-12 and interferon (IFN)-gamma were determined.Results. ***Flt3L*** pretreatment increased the synthesis of CD40-inducible IL-12 p40 but not of bioactive p70. Coculture with anti-IL-10 antibody increased p70 production. Combined Flt3L and single-dose anti-IL-10 antibody pretreatment improved lesion cure rates from 40% to 87% relative to mice pretreated with rFlt3L only (P < .01 chi(2) test) and increased T helper 1 (Th1)-type cytokine production 4 weeks after infection but did not cure Rag-2- and IFN-gamma-knockout BALB/c mice. Flt3L and anti-IL-10 antibody pretreatments increased frequencies of IL12- and IFN-gamma-secreting cells 2 and 4 days after infection. Both natural killer and CD4(+) cells contributed to increased early IFN-gamma production.Conclusion. A single dose of anti-IL-10 antibody significantly improves Flt3L immunoprophylaxis against infection mediated by Th1-type adaptive responses.

11/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0015573520 BIOSIS NO.: 200510268020
Acceleration and enhancement of T-cell recovery and immune competence by Flt3-ligand (Flt3L) following BMT with low numbers of progenitor cells in immune deficient mice.
AUTHOR: Wils Evert-Jan (Reprint); Broers Annoek E C; Verjans Georges M G M; Niesters Bert; Osterhaus Albert D M E; Spits Hergen; Lowenberg Bob; Wagemaker Gerard; Braakman Erik; Cornelissen Jan J
AUTHOR ADDRESS: Erasmus Univ, Ctr Med, Rotterdam, Netherlands**Netherlands
JOURNAL: Blood 104 (11, Part 1): p17A NOV 16 2004 2004
CONFERENCE/MEETING: 46th Annual Meeting of the

American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;
20041204
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Deficient thymopoiesis and a retarded or absent recovery of newly developed CD4(+) T-cells has become one of the most important determinants of impaired immune competence in the later time period after allogeneic transplantation. We previously showed that Interleukin-7 (IL-7) may enhance peripheral T-cell expansion without affecting thymopoiesis after BMT in immunodeficient mice (Broers et al. Blood 2003). In order to improve thymopoiesis, we evaluated whether the cytokine Flt3L alone or combined with IL-7 would affect thymopoiesis and/or the generation of lymphoid progenitors following BMT in immunodeficient RAG-2(-/-), gamma c(-/-) mice, lacking T-, B- and NK-cells. Following 3 Gy irradiation and transplantation of graded restricted numbers of T-cell depleted (TCD) BM, mice received Flt3L (3 x 20 mu g/week), IL-7 (35 x 5 mu g/week) or the combination of IL-7 and Flt3L until 80 days after BMT. Hematopoietic recovery was evaluated weekly by flowcytometry. While B-cell and NK-cell recovery were moderately enhanced, Flt3L strongly accelerated and enhanced the recovery of T-cells, especially in the setting of BMT with a low dose of 4 x 10⁴ TCD-BM. In contrast, T-cell recovery was still insufficient in control mice treated with PBS (p < 0.01) or mice treated with IL-7 alone by day 80 after BMT with 4 x 10⁴ TCD-BM. The combination of Flt3L and IL-7 did not result in better recovery as compared to Flt3L alone. As early concurrent enhanced T-cell, B-cell, NK-cell and myeloid recovery may suggest an effect on lymphoid progenitors, the number of common lymphoid progenitors (CLP) as characterized by lineage(-), IL-7 R alpha(+), sca-1(low) and AA4.1(+) was assessed. At day 20 post-BMT, 13.2 x 10³ (+/- 10) CLP were harvested from the BM of Flt3L treated mice versus 3.9 x 10³ (+/- 0.6) from control PBS treated mice (p = 0.2). Furthermore, thymic cellularity was increased (18.6 (+/- 8) x 10⁶ thymocytes versus 6.6 (+/- 0.4) x 10⁶, p = 0.1) and especially the number of double positive CD4/CD8 thymocytes were increased in Flt3L treated mice (14.3 x 10⁶ (+/- 7) versus 2.3 x 10⁶ (+/- 1), p = 0.03) at day 20 post-BMT. Next, we studied whether enhanced hematopoietic recovery following Flt3L would result in better immune competence by evaluating survival and clearance of viral load after opportunistic murine cytomegalovirus (mCMV) ***infection***. RAG-2(-/-), gamma c(-/-) mice were transplanted with 4 x 10⁴ TCD-BM and subsequently ***infected*** intraperitoneally with 10⁴ PFU mCMV at day 28 post-BMT. All Flt3L treated mice survived and rapidly cleared their viral load as assessed by quantitative real-time Taqman PCR in plasma. T-cell numbers were inversely correlated with viral load (r = -0.467, p = 0.04), while numbers of NK-cells, B-cells or granulocytes were not associated with viral load. A 100% mortality was observed in control mice developing a viral load > 2 x 10⁵ geq/ml. These results suggest that Flt3L may restore T-cell recovery and immune competence especially in the setting of transplantation with restricted numbers of progenitor cells by promoting thymopoiesis. Enhanced thymopoiesis directly mediated by Flt3L or expansion of lymphoid progenitors by Flt3L may account for the higher numbers of newly developed T-cells.

11/7/4 (Item 4 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rights reserved.

0015234870 BIOSIS NO.: 200500141935

Enhancement of dendritic cell production by Fms-like tyrosine kinase-3 ligand increases the resistance of mice to a burn wound infection

AUTHOR: Toliver-Kinsky Tracy E (Reprint); Cui Weihua; Murphey Erle D; Lin Chengyie; Sherwood Edward R

AUTHOR ADDRESS: Med.BranchDept Anesthesiol, Univ Texas, 301 Univ Blvd, Galveston, TX, 77555, USA**USA

AUTHOR E-MAIL ADDRESS: ttoliver@utmb.edu

JOURNAL: Journal of Immunology 174 (1): p404-410 January 1, 2005 2005

MEDIUM: print

ISSN: 0022-1767 (ISSN print)

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Fms-like tyrosine kinase-3 ligand (Flt3L) is a hemopoietic cytokine that stimulates the production of dendritic cells. This study evaluated the ability of Flt3L-enhanced dendritic cell production to increase the resistance of mice to a burn wound infection with *Pseudomonas aeruginosa*, a common source of infections in burn patients that have, impaired immunity and are susceptible to opportunistic microorganisms. ***Treatment*** of mice with ***Flt3L*** for 5 days caused a significant increase in dendritic cell numbers in the spleen and significantly increased survival upon a subsequent burn wound ***infection***. Improved survival in ***Flt3L*** - ***treated*** mice was associated with limited bacterial growth and spread within the burn wounds and a decrease in systemic dissemination of *P. aeruginosa*. Resistance to burn wound infection could also be conferred to recipient mice by the adoptive transfer of dendritic cells that had been isolated from spleens of ***Flt3L*** - ***treated*** mice. Adoptive transfer of the same number of splenic dendritic cells from nontreated mice did not confer resistance to burn wound ***infection***. These data indicate that ***Flt3L*** can increase the resistance of mice to a *P. aeruginosa* burn wound infection through both stimulation of dendritic cell production and enhancement of dendritic cell function.

11/7/5 (Item 5 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015073146 BIOSIS NO.: 200400441065

Short-term Flt3L treatment effectively mobilizes functional macaque dendritic cells

AUTHOR: Teleshova Natalia; Jones Jennifer; Kenney Jessica; Purcell Jeanette ; Bohm Rudolf; Gettie Agegnehu; Pope Melissa (Reprint)

AUTHOR ADDRESS: Ctr Biomed Res, Populat Council, 1230 York Ave, New York, NY, 10021, USA**USA

AUTHOR E-MAIL ADDRESS: mpope@popcbr.rockefeller.edu

JOURNAL: Journal of Leukocyte Biology 75 (6): p1102-1110 June 2004 2004

MEDIUM: print

ISSN: 0741-5400 (ISSN print)

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: In vivo administration of soluble Flt3L increases dendritic cell (DC) numbers to favor improved DC targeting of vaccine antigens, augmenting vaccine efficiency. In addition to confirming the effectiveness of human Flt3L in macaques, we strove to determine the optimal regimen to elevate numbers of functional DCs. Circulating DCs were identified within lineage-human leukocyte antigen-DR+ cells, which

comprised CD11c-CD123+ plasmacytoid DCs (PDCs) and CD123- cells including CD11c+CD123- myeloid DCs as well as CD11c-CD123- cells. Traditionally, DCs have been monitored 1-2 days after 10- to 14-day treatments with Flt3L (100 mug/kg/day). We demonstrate that although standard treatment increased macaque DC percentages, as little as 5-7 days of treatment was sufficient, if not more effective at mobilizing DCs. Moreover, DC frequency continued to escalate over the ensuing days, peaking at approx 4 days post 7 days of treatment and ultimately decreasing thereafter. As expected, there was a more pronounced increase in the percentages and actual numbers of CD123- cells (CD11c+ and CD11c- subsets) compared with PDCs. Flt3L-mobilized DCs exhibited slightly increased CD80/CD86 expression but typically still that of immature DCs and were resilient to freeze-thawing. Overnight culture activated the cells, up-regulating CD80/CD86 expression as well as interleukin-12 release, typically being boosted by CD40L. This was even more apparent for enriched DC cultures. These data verify that peak mobilization of large numbers of functional macaque DCs occurs a few days, not immediately, after short-term ***Flt3L*** dosing. This has important implications for improved DC-targeting vaccine strategies to prevent infection with human immunodeficiency virus and other pathogens.

11/7/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014811839 BIOSIS NO.: 200400192596
Increased dendritic cell numbers impair protective immunity to intracellular bacteria despite augmenting antigen-specific CD8+ T lymphocyte responses.
AUTHOR: Alaniz Robert C; Sandall Sharsti; Thomas Elaine K; Wilson Christopher B (Reprint)
AUTHOR ADDRESS: Department of Immunology, University of Washington, 1959 NE Pacific Street, Box 357650, Seattle, WA, 98195, USA**USA
AUTHOR E-MAIL ADDRESS: cbwilson@u.washington.edu
JOURNAL: Journal of Immunology 172 (6): p3725-3735 March 15, 2004 2004
MEDIUM: print
ISSN: 0022-1767 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Dendritic cells (DCs) reside in tissues, where they function as sentinels, providing an essential link between innate and adaptive immunity. Increasing the numbers of DCs in vivo augments T cell responses, and can cause dramatic CTL-dependent tumor regression. To determine whether greater DC numbers promoted T cell-mediated protection in the context of host defense against intracellular bacteria, we treated mice with Flt3 ligand (Flt3-L) to increase DCs in vivo and challenged them with *Listeria monocytogenes*. Unexpectedly, after primary challenge with *Listeria*, the overall control of *Listeria* infection was impaired in Flt3-L-treated mice, which had greater bacterial burden and mortality than controls. Similar results were obtained when DC numbers were increased by treatment with polyethylene glycol-conjugated GM-CSF rather than Flt3-L and in mice ***infected*** with *Mycobacterium tuberculosis*. Impaired protection was not due to dysfunctional T cell responses, as Flt3-L-treated mice had a greater frequency and absolute number of Ag-specific CD8+ T cells, which produced IFN-gamma, exhibited cytolytic activity, and transferred protection. The increased *Listeria* burden in Flt3-L-treated mice was preferentially associated with DCs, which were unable to kill *Listeria* and more resistant to CTL lysis compared with

macrophages in vitro. Although we cannot exclude the possibility that other potential effects, in addition to increased numbers of DCs, are shared by Flt3-L and polyethylene glycolconjugated GM-CSF and contributed to the increase in susceptibility observed in treated mice, these results support the notion that DC numbers must be properly controlled within physiological limits to optimize host defense to intracellular bacterial pathogens.

11/7/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014801867 BIOSIS NO.: 200400172624

Pim-1 is upregulated in constitutively activating FLT3 mutants and is one of components of the cell survival.

AUTHOR: Kim Kyu-Tae (Reprint); Baird Kristin; Ahn Joon-Young (Reprint); Meltzer Paul; Small Donald (Reprint)

AUTHOR ADDRESS: Sydney Kimmel Comprehensive Cancer Centre, Johns Hopkins Medical Institution, Baltimore, MD, USA**USA

JOURNAL: Blood 102 (11): p172a November 16, 2003 2003

MEDIUM: print

CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Constitutively activating internal tandem duplication (ITD) and point mutations of the receptor tyrosinekinase FLT3 are present in approximately 30% of patients with acute myeloid leukemia (AML). FLT3 mutations are likely to be important because their presence is associated with poor prognosis. Both types of mutations appear to activate the tyrosine kinase activity of FLT3. We were interested in the changes in gene-expression mediated by constitutively activated FLT3. The indolocarbazole derivative CEP-701 potently and selectively inhibits autophosphorylation of wild-type and constitutively activated mutant FLT3 in vitro in human and mouse FLT3-expressing myeloid leukemia-derived cell lines. To determine changes in gene expression, RNA harvested from myeloid leukemia-derived cell lines expressing activated FLT3, before and after incubation with FLT3 inhibitors, was hybridized to cDNA microarrays. Several genes showed significant changes in response to FLT3 inhibition by 50 nM CEP701 for 2h to 6h. Among the genes most consistently affected was Pim-1, which was down-regulated upon FLT3 inhibition. Pim-1 is a serine-threonine kinase involved in anti-apoptotic signaling in hematopoietic progenitor cells. Pim-1 was originally isolated as a proviral insertion site that cooperated in the process of leukemogenesis and it has been shown to synergize with the nuclear transcription factor Myc in blocking apoptosis and transforming hematopoietic cells. Pim-1 expression has been shown to be enhanced by STAT5, which is a downstream target of FLT3. We confirmed the results from the microarrays with real-time quantitative PCR (QPCR) from different human FLT3 expressing myeloid leukemia-derived cell lines including EOL-1, MV4-11, and FLT3/ITD transformed TF1, BaF3, and 32D cells. The mRNA levels of Pim-1 exhibited approximately 10-fold decrease in EOL-1, MV4-11 and FLT3-ITD transformed cells with FLT3 inhibition. We also have found protein levels of pim-1 decreased in response to FLT3 inhibitions and they are parallel with autophosphorylation activity of FLT3. Further more, we have found pim-1 is highly expressed in FLT3/ITD transformed cells without induction of cytokines comparing

to their parental cells. To determine biological functions of pim-1 in cells, we infected FLT3/ITD transformed BaF3 with wild-type pim-1s or dominant negative pim-1. Enforced 44kd of pim-1 or 33kd of pim-1 expression made cells more resistant to cytotoxicity derived from CEP-701, while dominant negative pim-1 expression made cells die more quickly. Furthermore, dominant negative mutant pim-1 expression accelerated the apoptosis of the cells induced by CEP-701. These findings suggest that FLT3 may up-regulate Pim-1 in leukemia cells and be part of the pathway by which FLT3 transforms cells and up-regulated pim-1 may partly contribute constitutive proliferation and antiapoptosis in FLT3 transformed cells.

11/7/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014746178 BIOSIS NO.: 200400116935

Adenovirus-mediated Flt3L-gene therapy protects against colon cancer metastasis in a BALB/c mouse model.

AUTHOR: Riediger Carina (Reprint); Wingeuder Gerhard; Knolle Percy; Stremmel Wolfgang (Reprint); Encke Jens (Reprint)

AUTHOR ADDRESS: Dept. of Internal Medicine IV, Heidelberg, Germany**Germany

JOURNAL: Hepatology 38 (4 Suppl. 1): p405A October 2003 2003

MEDIUM: print

CONFERENCE/MEETING: 54th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, USA October 24-28, 2003; 20031024

SPONSOR: American Association for the Study of Liver Diseases

ISSN: 0270-9139 (ISSN print)

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Flt3(fms-like tyrosine kinase 3)ligand (Flt3L) is a potent hematopoietic cytokine that effects growth and differentiation of progenitor and stem cells. It also augments the numbers of dendritic cells (DC) and natural killer (NK) cells in mice and humans. DC are the key mediators in antigen presentation and in the induction and regulation of immune responses. Therefore they are thought to play a major role in the anti-tumor activity. In this study we describe a gene-therapeutic approach to stimulate antitumor immunity by a novel adenoviral-mediated transfer of Flt3L to treat liver metastasis. We generated and produced an adenovirus expressing the Flt3L gene (pAdFlt3L) and confirmed expression by Western Blot and ELISA technique: in vitro infection of a mouse colon carcinoma cell line (CT26) with adenoviral vector expressing Flt3L (pAdFlt3L) induced high levels of Flt3L in the supernatants as well as in the cell lysates. We injected CT26 cells subcutaneously into the flank of 4-week-old, female BALB/c mice as a model of colon carcinoma liver metastasis. After 13 days tumor nodules were palpable. Flt3L immunotherapy was initiated 13 days after tumor inoculation by injecting 109 pAdflt3L i.v. into the tail vein or directly into the tumor. High levels of Flt3L in the serum of pAdflt3L-treated mice during the first 3 days after i.v. as well as i.t. injection were detected by ELISA with a maximum Flt3L level after 24hours, but with an approximately 1000 to 10000 fold higher Flt3L level after i.v.-treatment. Interestingly animals with a second injection 7 days after the first showed a second peak of Flt3L-levels showing the low immunogenicity of the adenoviral vector. Spleen size and weight was strongly augmented in mice treated with pAdFlt3L. Flowcytometric analysis showed that therapy with pAdFlt3L caused a remarkable increase of DC (CD11c+/CD11b+). Furthermore we vaccinated a group of mice with CT26-cell-lysate and coinjected the

Flt3L-adenovirus s.c. Mice in the vaccinated group were challenged with the CT26 cell line; while in the control group all mice died, in the vaccination group a 100% survival was observed, demonstrating the potential of costimulation with Flt3L. Our results indicate that immunostimulatory anti-tumor effects against colon carcinoma liver metastasis are provided by Flt3L adenoviral therapy both by direct application and by coimmunization through stimulation and proliferation of DCs.

11/7/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014528704 BIOSIS NO.: 200300486361

Dendritic cell subsets in blood and lymphoid tissue of rhesus monkeys and their mobilization with Flt3 ligand.

AUTHOR: Coates P Toby H; Barratt-Boyes Simon M; Zhang Linyou; Donnenberg Vera S; O'Connell Peta J; Logar Alison J; Duncan F Jason; Murphey-Corb Michael; Donnenberg Albert D; Morelli Adrian E; Maliszewski Charles R; Thomson Angus W (Reprint)

AUTHOR ADDRESS: 200 Lothrop St, W1544 Biomedical Science Tower, Pittsburgh, PA, 15217, USA**USA

AUTHOR E-MAIL ADDRESS: thomsonaw@msx.upmc.edu

JOURNAL: Blood 102 (7): p2513-2521 October 1, 2003 2003

MEDIUM: print

ISSN: 0006-4971

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: We provide phenotypic and functional evidence of premonocytoid dendritic cells (DCs) and preplasmacytoid DCs in blood and of corresponding DC subsets in secondary lymphoid tissue of rhesus monkeys. Subsets were identified and sorted by 4-color flow cytometry using antihuman monoclonal antibodies cross-reactive with rhesus monkey. To mobilize pre-DC subsets, fms-like tyrosine 3 kinase ligand (Flt3L; 100 mug/kg subcutaneously) was administered for 10 days. Presumptive pre-DC subsets were identified within the lineage- (Lin-) major histocompatibility complex (MHC) class II+ fraction of blood mononuclear cells. Premonocytoid DCs were CD11c+CD123- (interleukin-3Ralpha- (IL-3Ralpha-)). Preplasmacytoid DCs were characterized as CD11c-CD123++. Flt3L increased the CD11c+ pre-DC (7-fold) and CD123++ pre-DC subsets (3-fold) in blood. The freshly isolated CD11c+ pre-DC subset induced modest proliferation of naive allogeneic T cells. After overnight culture with granulocyte macrophage-colony-stimulating factor (GM-CSF) and CD40L, both subsets up-regulated surface costimulatory molecules, and CD11c+ pre-DCs became potent allostimulators. Freshly isolated CD123++ pre-DCs showed typical plasmacytoid morphology and, when cultured with IL-3 and CD40L for 72 hours, developed mature DC morphology. Following stimulation with CD40L, CD11c+ pre-DCs secreted increased levels of IL-12p40. Importantly, herpes simplex virus-stimulated CD123++ pre-DCs, but not CD11c+ pre-DCs, secreted interferon-alpha (IFN-alpha). Corresponding DC subsets were identified by flow analysis and immunohistochemistry in lymph nodes wherein both populations were increased 2- to 3-fold by ***Flt3L*** administration. CD123+ pre-DCs produced IFN-alpha in response to in vivo viral ***infection***. Thus, rhesus monkeys exhibit 2 distinct DC precursor populations that closely resemble those of humans. Both are mobilized into blood and lymphoid tissue by Flt3L, offering potential for their further characterization and possible ***therapeutic*** application.

11/7/10 (Item 10 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014397571 BIOSIS NO.: 200300356290

Potential Activation of Pre-Leukemic Events by Retroviral Over-Expression of HoxA9 in Human CD34+ Cells.

AUTHOR: Neering Sarah J (Reprint); Guzman Monica L; Echlin-Bell Deborah R; Swiderski Carol F; Vanin Elio F; Sauvageau Guy; Jordan Craig T

AUTHOR ADDRESS: Hematology/Oncology, Markey Cancer Center, Lexington, KY, USA**USA

JOURNAL: Blood 100 (11): pAbstract No. 238 November 16, 2002 2002

MEDIUM: print

CONFERENCE/MEETING: 44th Annual Meeting of the American Society of Hematology Philadelphia, PA, USA December 06-10, 2002; 20021206

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Recent studies have established HoxA9 as a potent regulator of self-renewal in mouse stem cells and as a contributing factor to leukemia in mouse model systems. In addition, gene expression studies in primary human leukemia specimens have identified HoxA9 up-regulation as the most common molecular characteristic of acute myeloid leukemia (AML). Thus, aberrant expression of HoxA9 is strongly implicated in the leukemogenic process; however, potential mechanisms of transformation by HoxA9 are largely unknown. In the present study we established a novel model system in which to examine the effects of both HoxA9 expression, as well as the leukemic translocation Nup98/HoxA9, in primary human stem/progenitor cells. Retroviral vector plasmids encoding HoxA9 or Nup98/HoxA9, and the green fluorescent protein (GFP), were transfected into the phoenix-ampho retrovirus packaging cell line. Amphotropic viral supernatants were then harvested and used to repeatedly infect a second packaging line, FLY-RD18, which expresses the feline leukemia virus envelope RD114. This process yielded producer cells that secrete high titer virus pseudotyped with the RD114 envelope. Viruses employing the RD114 envelope have previously been shown to infect human CD34+ cells very efficiently. Experiments were then performed to analyze expression of each virus in CD34+ cells isolated from umbilical cord blood (CB) or adult marrow. For infection, CD34+ cells were plated in 35 mm transwell inserts (0.45 micron pore, collagen coated), and cultured for 24 hours in serum-free medium (SFM) plus IL-6, SCF, and FL (10ng/ml each). Next, 4-5 mls of viral supernatant were added to the upper chamber of each transwell and allowed to flow through the membrane to the lower chamber. This procedure was repeated three times over a 48-hour period. Each infected population was then cultured for two days in SFM + IL-6, SCF, and FL. Analysis by flow cytometry showed infection efficiencies ranging from 30-60% for CB CD34+ cells, suggesting that the combination of RD114 pseudotype and the flow-through infection method is a highly effective strategy for transduction of primary hematopoietic cells. Progenitor assays of CD34+/GFP+ cells in methylcellulose culture indicated that expression of Nup98/HoxA9 strongly inhibited erythroid colony formation but had no significant effect on myeloid colony formation. Immunophenotypic analyses of HoxA9 and Nup98/HoxA9 infected cells showed substantial up-regulation of the transmembrane tyrosine kinase receptor Flt3, which has been shown to be frequently activated in AML. Interestingly, HoxA9 and Nup98/HoxA9 infected cells also demonstrated increased expression of the IL-3 receptor alpha chain, CD123. We and others have previously shown that up-regulation of CD123 is a common event in acute

leukemia. Finally, to further characterize these observations, we tested infection of the leukemic cell line TF-1. Expression of HoxA9 in TF-1 cells also increased expression of Flt3 as assessed by immunophenotype and western blot analysis. Collectively, these data suggest that one aspect of HoxA9 transforming activity may be to increase expression of the Flt3 and CD123 genes, both of which are implicated in primary human AML.

11/7/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014383936 BIOSIS NO.: 200300340679
Stimulation of hematopoiesis by the Fms-like tyrosine kinase 3 ligand restores bacterial induction of Th1 cytokines in thermally injured mice.
AUTHOR: Toliver-Kinsky Tracy E (Reprint); Lin Cheng Y; Herndon David N; Sherwood Edward R
AUTHOR ADDRESS: Department of Anesthesiology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555-0591, USA**USA
AUTHOR E-MAIL ADDRESS: ttoliver@utmb.edu
JOURNAL: Infection and Immunity 71 (6): p3058-3067 June 2003 2003
MEDIUM: print
ISSN: 0019-9567 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Patients with large burn injuries are susceptible to opportunistic infections due to impaired functions of multiple effector cells of innate immunity and acquired immunity, including macrophages, dendritic cells (DC), natural killer (NK) cells, and T cells. The ability of a host to produce Th1 cytokines, such as gamma interferon (IFN-gamma) and interleukin-12 (IL-12), upon infectious challenge is also impaired after burn injury. Stimulation of hematopoiesis, to regenerate new immune cells, may be an effective strategy for improving resistance to infections after severe burn trauma. Fms-like tyrosine kinase 3 ligand (Flt3L) is a hematopoietic cytokine that stimulates the expansion and differentiation of NK cells and DC. Using a mouse model, we tested the hypothesis that Flt3L treatments after burn injury stimulate the production of functional effector cells of innate immunity and restore appropriate Th1 cytokine responses to *Pseudomonas aeruginosa*, a common source of pneumonia and wound ***infections*** in burn victims. Flt3L increased splenic cellularity in sham (uninjured) and burned mice and increased the numbers of NK cells (DX5+) and DC (CD11c+). In response to *P. aeruginosa*, significant increases in the serum IFN-gamma levels and the numbers of splenic IFN-gamma-producing DC, NK cells, and T cells were observed in Flt3L-treated burned mice compared to the values obtained for untreated burned mice. The splenic levels of IL-12 and IL-15 mRNAs and the IL-12 and IL-15 receptors were also increased. In addition, Flt3L treatment restored the ability of splenic cultures prepared from burned mice to produce IFN-gamma and IL-12 after in vitro challenge with *P. aeruginosa*. Flt3L may have potential for restoring NK cell and DC functions and improving immunity after burn injury.

11/7/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0014205576 BIOSIS NO.: 200300164295
Flt3 ligand-treated neonatal mice have increased innate

immunity against intracellular pathogens and efficiently control virus
infections

AUTHOR: Vollstedt Sabine; Franchini Marco; Hefti Hans P; Odermatt Bernhard;
O'Keefe Meredith; Alber Gottfried; Glanzmann Bettina; Riesen Matthias;
Ackermann Mathias; Suter Mark (Reprint)

AUTHOR ADDRESS: Institute of Virology, University of Zurich,
Winterthurerstr. 266a, 8057, Zurich, Switzerland**Switzerland

AUTHOR E-MAIL ADDRESS: msuter@vetvir.unizh.ch

JOURNAL: Journal of Experimental Medicine 197 (5): p575-584 March 3, 2003
2003

MEDIUM: print

ISSN: 0022-1007 (ISSN print)

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Flt-3 ligand (FL), a hematopoietic growth factor, increases the number of dendritic cells (DCs), B cells, and natural killer cells in adult mice but the effect in neonates was unknown. We show that FL treatment of newborn mice induced a >100-fold increase in the innate resistance against infection with herpes simplex virus type 1 and *Listeria monocytogenes*. This resistance required interferon (IFN)-alpha/beta for viral and interleukin (IL)-12 for bacterial infections. Long-term survival after viral but not bacterial infection was increased approx100-fold by FL treatment. After treatment, CD11c+/major histocompatibility complex type II+ and CD11c+/B220+ DC lineage cells were the only cell populations increased in the spleen, liver, peritoneum, and skin. DC induction was independent of IFNs, IL-2, -4, -7, -9, -15, and mature T and B cells. The data suggest that FL increases the number of DCs in neonates and possibly in other immune-compromised individuals, which in turn improves IFN-alpha/beta- and IL-12-associated immune responses.

11/7/13 (Item 13 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0013776931 BIOSIS NO.: 200200370442

Flt3L induces antileishmanial immunity independent of eventual CD4+ Th cell phenotype

AUTHOR: Das Lopamudra (Reprint); Heinzel Frederick P (Reprint)

AUTHOR ADDRESS: Geographic Medicine, Case Western Reserve University, 2109
Adelbert Rd, Cleveland, OH, 44106-4983, USA**USA

JOURNAL: FASEB Journal 16 (5): pA1037 March 22, 2002 2002

MEDIUM: print

CONFERENCE/MEETING: Annual Meeting of Professional Research Scientists on
Experimental Biology New Orleans, Louisiana, USA April 20-24, 2002;

20020420

ISSN: 0892-6638

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: We hypothesized that in vivo expanded dendritic cells (DC) would induce curative Th1 T cells and protect against infection with >Leishmania major. Susceptible, Th2-biased BALB/c mice ***treated*** with Flt3 ligand (Flt3L) for 10 days increased DC numbers and production of IL-12 p40 in vivo. Parasite numbers were reduced and lesion progression stopped in 40% of treated animals, but Th2 responses were maintained. Although CD40-stimulated splenocytes of Flt3L-treated mice produced 20-fold more IL-12 p40 than controls, IL-12 p70 only increased

2-fold. IL-12 p70 production in vitro was increased with addition of LPS, anti-IL-10 or IL-4, suggesting increased DC maturity would promote Th1 cells in vivo. Although LPS reversed Flt3L-induced protection, anti-IL-10 and Flt3L-treated BALB/c mice were uniformly resistant, while mice treated with Flt3L or anti-IL-10 alone progressed. However, Th2-biased T cell responses persisted despite lesion resolution. These findings suggest parasite killing by Flt3L-recruited innate cellular immunity and identify a model of anti-infective immunotherapy against intracellular parasitism that is dissociated from T cell differentiation.

11/7/14 (Item 14 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013228816 BIOSIS NO.: 200100400655

Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: Studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L)

AUTHOR: Bruserud Oystein (Reprint); Foss Brynjar; Petersen Hein

AUTHOR ADDRESS: Department of Medicine, Haukeland University Hospital, N-5021, Bergen, Norway**Norway

JOURNAL: European Cytokine Network 12 (2): p231-238 April-June, 2001 2001

MEDIUM: print

ISSN: 1148-5493

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: The levels of hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders were investigated using a variety of approaches. Firstly, serum levels of granulocyte-macrophage colony-stimulating factor (GM-CSF), G-CSF and Flt3L (Flt3L) were examined in acute leukemia patients with treatment-induced cytopenia and complicating bacterial ***infections***. Increased serum levels of both G-CSF and ***Flt3***-ligand (Flt3L) were detected when these patients developed therapy-induced leukopenia, whereas GM-CSF levels were low or undetectable. Development of complicating bacterial ***infections*** then increased the serum levels of both G- and GM-CSF, and the Flt3L levels remained high during the ***infections***. Secondly, release of growth factors was characterized for clonogenic T cells that remained in the circulation of acute leukemia patients with chemotherapy-induced cytopenia. CD4+ and CD8+ T cells from these patients released high levels of GM-CSF, relatively low levels of IL-3 secretion having been detected, and only a minority of the clones released detectable amounts of Flt3L. Thus, circulating T cells may contribute to the high systemic growth factor levels in cytopenic patients. Thirdly, plasma levels of GM-CSF and interleukin-3 (IL-3) were examined in patients with malignant disorders who received chemotherapy plus G-CSF for stem cell mobilization. Increased levels of GM-CSF and Flt3L were detected both in the patients' plasma and in the stem cell grafts. Despite the increased growth factor levels in neutropenic patients with complicating infections, the occurrence of febrile neutropenia did not have a major impact on normal hematopoietic reconstitution (i.e. duration of treatment-induced neutropenia) after intensive chemotherapy for acute myelogenous leukemia.

11/7/15 (Item 15 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.

0013003681 BIOSIS NO.: 200100175520

Flt3 ligand pretreatment promotes protective immunity to *Listeria monocytogenes*

AUTHOR: Gregory Stephen H (Reprint); Sagnimeni Athanasia J; Zurowski Nancy B; Thomson Angus W

AUTHOR ADDRESS: Department of Medicine, Rhode Island Hospital/Brown University School of Medicine, 55 Claverick Street, 432 Pierre M. Galletti Building, Providence, RI, 02903, USA**USA

JOURNAL: Cytokine 13 (4): p202-208 21 February, 2001 2001

MEDIUM: print

ISSN: 1043-4666

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Flt3 ligand (Flt3L) plays a critical role in the proliferation, differentiation and survival of haematopoietic progenitor cells. Its potential use in a clinical setting has been suggested. Here, we report that mice administered Flt3L displayed a nine-fold increase in size of their hepatic non-parenchymal cell population and an approximate 365-fold increase in number of mature dendritic cells within their livers. Such mice exhibited an elevated resistance to secondary infections with *Listeria monocytogenes*, an intracellular bacterial pathogen. More than 2.0 log10 fewer listeriae were recovered in the livers of ***Flt3L*** - treated, than untreated, mice on day 2 following secondary challenge. Importantly, Flt3L-pretreated mice immunized with an avirulent (*listeriolysin* O-negative) strain of *Listeria* harbored significantly fewer (approx 1.5 log10) organisms in their spleens and livers than did control mice immunized with *listeriolysin* O-negative listeriae and challenged with a lethal dose of bacteria. The latter finding supports a potential role for Flt3L in strategies to develop vaccines to intracellular pathogens.

11/7/16 (Item 16 from file: 5)

DIALOG(R) File 5: Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rights reserved.

0012969863 BIOSIS NO.: 200100141702

Pretreatment with recombinant Flt3 ligand partially protects against progressive cutaneous leishmaniasis in susceptible BALB/c mice

AUTHOR: Kremer Inger B; Gould Meetha P; Cooper Kevin D; Heinzl Frederick P (Reprint)

AUTHOR ADDRESS: Division of Geographic Medicine, Case Western Reserve University School of Medicine, W-137, Cleveland, OH, 44106-4983, USA**USA

JOURNAL: Infection and Immunity 69 (2): p673-680 February, 2001 2001

MEDIUM: print

ISSN: 0019-9567

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Dendritic cells are potent antigen-presenting cells that also produce interleukin-12 (IL-12) during innate and adaptive cellular immune responses and that thereby promote the differentiation of gamma interferon (IFN-gamma)-producing Th1-type CD4+ T lymphocytes. We hypothesized that expanded dendritic-cell populations in mice pretreated with the hematopoietic cytokine Flt3L would protect against cutaneous *Leishmania major* infection. Pretreatment of disease-susceptible BALB/c mice with 10 mug of recombinant Flt3L (rFlt3L) for 9 to 10 days before infection increased lymph node IL-12 p40 productive capacity 20-fold

compared to that of saline-injected controls. Furthermore, 9 of 22 (40.9%) rFlt3L-pretreated BALB/c mice resolved their cutaneous ***infections***, whereas none of the 22 control BALB/c mice healed. Healed, rFlt3L-pretreated mice did not develop disease following reinfection. ***Flt3L*** pretreatment also reduced parasite numbers 1,000-fold in the cutaneous lesions at 2 weeks after infection relative to numbers in lesions of untreated controls. However, ***Flt3L*** pretreatment did not significantly alter L. major-induced IFN-gamma and IL-4 production in lymph node culture at 1, 2, and 4 weeks after ***infection***. Despite the lack of Th immune deviation, Flt3L ligand-pretreated lymph nodes expressed up to 10-fold higher levels of IL-12 p40 and inducible (type 2) nitric oxide synthase mRNA at 7 days after ***infection***. In contrast, ***treatment*** with rFlt3L after infection failed to protect against disease despite comparable expansions of dendritic cells and IL-12 p40 productive capacity in both infected and uninfected BALB/c mice treated with rFlt3L. We conclude that rFlt3L pretreatment before infection with L. major reduces parasite load and promotes healing of cutaneous lesions without stable cytokine deviation towards a dominant Th1 cytokine phenotype.

11/7/17 (Item 17 from file: 5)
 DIALOG(R) File 5:Biosis Previews(R)
 (c) 2006 The Thomson Corporation. All rts. reserv.

0012802298 BIOSIS NO.: 200000520611
 Effect of CD40 ligand and other immunomodulators on Pneumocystis carinii infection in rat model
 AUTHOR: Oz Helieh S (Reprint); Hughes Walter T; Rehg Jerold E; Thomas Elaine K
 AUTHOR ADDRESS: Department of Internal Medicine, University of Kentucky Medical Center, Lexington, KY, 40536, USA**USA
 JOURNAL: Microbial Pathogenesis 29 (3): p187-190 September, 2000 2000
 MEDIUM: print
 ISSN: 0882-4010
 DOCUMENT TYPE: Article
 RECORD TYPE: Abstract
 LANGUAGE: English

ABSTRACT: The corticosteroid-treated animal is well established as an experimental model for the study of Pneumocystis carinii pneumonitis (PCP). Latent or acquired infection with P. carinii in the murine lung progresses to fatal pneumonitis when the host is profoundly immunocompromized. In this study the effects of five immunomodulators; recombinant CD40 ligand (CD40L), bryostatin 1, recombinant FLT3 ligand (FLT3L), recombinant granulocyte colony-stimulating factor (G-CSF) and recombinant interleukin-15 (IL-15) were investigated against PCP in a dexamethasone immunosuppressed Sprague-Dawley rat model. The majority of rats (70%) treated with CD40L at the onset of dexamethasone immunosuppression were protected against PCP. When CD40L was given after 10 days of immunosuppression, only 40% of the rats resolved the ***infection***. However, 95% of the control animals developed PCP. Immunosuppressed rats treated with bryostatin 1, an immune activator had a partial (50%) protection against P. carinii ***infection***. In contrast, daily administration of ***FLT3L***, IL-15 or G-CSF provided no protection against P. carinii ***infection***.

11/7/18 (Item 18 from file: 5)
 DIALOG(R) File 5:Biosis Previews(R)
 (c) 2006 The Thomson Corporation. All rts. reserv.

0012543261 BIOSIS NO.: 200000261574

Polyomavirus-infected dendritic cells induce antiviral CD8+ T lymphocytes
AUTHOR: Drake Donald R III; Moser Janice M; Hadley Annette; Altman John D;
Maliszewski Charles; Butz Eric; Lukachèr Aron E (Reprint)

AUTHOR ADDRESS: Department of Pathology, Emory University School of
Medicine, 1639 Pierce Dr., Woodruff Memorial Research Building, Atlanta,
GA, 30322, USA**USA

JOURNAL: Journal of Virology 74 (9): p4093-4101 May, 2000 2000

MEDIUM: print

ISSN: 0022-538X.

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: CD8+ T cells are critical for the clearance of acute polyomavirus infection and the prevention of polyomavirus-induced tumors, but the antigen-presenting cell(s) involved in generating polyomavirus-specific CD8+ T cells have not been defined. We investigated whether dendritic cells and macrophages are permissive for polyomavirus infection and examined their potential for inducing antiviral CD8+ T cells. Although dendritic cells and macrophages both supported productive polyomavirus infection, dendritic cells were markedly more efficient at presenting the immunodominant viral epitope to CD8+ T cells. Additionally, infected dendritic cells, but not infected macrophages, primed anti-polyomavirus CD8+ T cells in vivo. ***Treatment*** with Flt3 ligand, a hematopoietic growth factor that dramatically expands the number of dendritic cells, markedly enhanced the magnitude of virus-specific CD8+ T-cell responses during acute infection and the pool of memory anti-polyomavirus CD8+ T cells. These findings suggest that virus-infected dendritic cells induce polyomavirus-specific CD8+ T cells in vivo and raise the potential for their use as cellular adjuvants to promote CD8+ T cell surveillance against polyomavirus-induced tumors.

11/7/19 (Item 1 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2006 Elsevier B.V. All rts. reserv.

12531313 EMBASE No: 2004122541

Increased Dendritic Cell Numbers Impair Protective Immunity to
Intracellular Bacteria Despite Augmenting Antigen-Specific CD8SUP+ T
Lymphocyte Responses

Alaniz R.C.; Sandall S.; Thomas E.K.; Wilson C.B.

Dr. C.B. Wilson, Department of Immunology, University of Washington, Box
357650, 1959 NE Pacific Street, Seattle, WA 98195 United States

AUTHOR EMAIL: cbwilson@u.washington.edu

Journal of Immunology (J. IMMUNOL.) (United States) 15 MAR 2004,
172/6 (3725-3735)

CODEN: JOIMA ISSN: 0022-1767

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 69

Dendritic cells (DCs) reside in tissues, where they function as sentinels, providing an essential link between innate and adaptive immunity. Increasing the numbers of DCs in vivo augments T cell responses, and can cause dramatic CTL-dependent tumor regression. To determine whether greater DC numbers promoted T cell-mediated protection in the context of host defense against intracellular bacteria, we treated mice with Flt3 ligand (Flt3-L) to increase DCs in vivo and challenged them with *Listeria monocytogenes*. Unexpectedly, after primary challenge with *Listeria*, the overall control of *Listeria* infection was impaired

in Flt3-L-treated mice, which had greater bacterial burden and mortality than controls. Similar results were obtained when DC numbers were increased by treatment with polyethylene glycol-conjugated GM-CSF rather than Flt3-L and in mice infected with Mycobacterium tuberculosis. Impaired protection was not due to dysfunctional T cell responses, as Flt3-L-treated mice had a greater frequency and absolute number of Ag-specific CD8SUP+ T cells, which produced IFN-gamma, exhibited cytolytic activity, and transferred protection. The increased Listeria burden in Flt3-L-treated mice was preferentially associated with DCs, which were unable to kill Listeria and more resistant to CTL lysis compared with macrophages in vitro. Although we cannot exclude the possibility that other potential effects, in addition to increased numbers of DCs, are shared by Flt3-L and polyethylene glycolconjugated GM-CSF and contributed to the increase in susceptibility observed in treated mice, these results support the notion that DC numbers must be properly controlled within physiological limits to optimize host defense to intracellular bacterial pathogens.

11/7/20 (Item 2 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

10733038 EMBASE No: 2000142755

Polyomavirus-infected dendritic cells induce antiviral CD8sup + T lymphocytes

Drake III D.R.; Moser J.M.; Hadley A.; Altman J.D.; Maliszewski C.; Butz E.; Lukacher A.E.

A.E. Lukacher, Department of Pathology, Emory University School of Medicine, Woodruff Memorial Research Building, 1639 Pierce Dr., Atlanta, GA 30322 United States

AUTHOR EMAIL: alukach@emory.edu

Journal of Virology (J. VIROL.) (United States) 2000, 74/9 (4093-4101)

CODEN: JOVIA ISSN: 0022-538X

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 64

CD8sup + T cells are critical for the clearance of acute polyomavirus infection and the prevention of polyomavirus-induced tumors, but the antigen-presenting cell(s) involved in generating polyomavirus-specific CD8sup + T cells have not been defined. We investigated whether dendritic cells and macrophages are permissive for polyomavirus infection and examined their potential for inducing antiviral CD8sup + T cells. Although dendritic cells and macrophages both supported productive polyomavirus infection, dendritic cells were markedly more efficient at presenting the immunodominant viral epitope to CD8sup + T cells. Additionally, infected dendritic cells, but not infected macrophages, primed anti-polyomavirus CD8sup + T cells in vivo. ***Treatment*** with ***Flt3*** ligand, a hematopoietic growth factor that dramatically expands the number of dendritic cells, markedly enhanced the magnitude of virus-specific CD8sup + T-cell responses during acute infection and the pool of memory antipolyomavirus CD8sup + T cells. These findings suggest that virus-infected dendritic cells induce polyomavirus-specific CD8sup + T cells in vivo and raise the potential for their use as cellular adjuvants to promote CD8sup + T cell surveillance against polyomavirus-induced tumors.

11/7/21 (Item 3 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2006 Elsevier B.V. All rts. reserv.

07411598 EMBASE No: 1998313000

Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: Implications for anti-cancer and anti-viral therapy

Shaw S.G.; Maung A.A.; Steptoe R.J.; Thomson A.W.; Vujanovic N.L.

Dr. N.L. Vujanovic, University of Pittsburgh Cancer Institute, W1045 Biomedical Science Tower, 211 Lothrop St., Pittsburgh, PA 15213 United States

Journal of Immunology (J. IMMUNOL.) (United States) 15 SEP 1998, 161/6 (2817-2824)

CODEN: JOIMA ISSN: 0022-1767

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 45

The generation and activity of NK cells appear to be regulated by a particular set of cytokines. We examined the in vivo effects of recombinant human Flt3 ligand (Flt3-L), a recently cloned potent hemopoietic cytokine, on NK cell development in mice. Daily i.p. administration of Flt3-L consistently induced striking increases in both the absolute number and the total cytotoxic activity of mature nonactivated NK cells within various tissues. Dose- and time-dependent increases were observed in the bone marrow (~2- and ~11-fold, respectively), thymus (~2.8- and ~2.0-fold), blood (~11- and ~15-fold), spleen (~10- and ~9-fold), and liver (~15- and ~39-fold). In addition, IL-2 induced a rapid increase in NK activity, NK cell proliferative responses, generation of lymphokine-activated killer activity, and development of activated adherent NK cells, which were all significantly increased by Flt3-L treatment. Thus, in addition to its recently reported capacity to stimulate dendritic cell production, Flt3-L has a prominent biologic role in NK cell generation in vivo. This is probably a result of selectively induced expansion of NK cell progenitors (pro-NK cells), because Flt3-L stimulates in vitro proliferation of pro-NK cells without affecting the cytotoxicity of mature NK cells. The results also indicate that either alone or in combination with a potent activator of NK cells, such as IL-2, Flt3-L could be used to markedly augment the number and activity of NK cells, especially in the liver. ***Flt3*** -L appears to have considerable potential for therapy of both cancer and viral ***infection***.

11/7/31 (Item 9 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2006 American Chemical Society. All rts. reserv.

140302117 CA: 140(19)302117g JOURNAL

Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion

AUTHOR(S): Sevilla, Noemi; McGavern, Dorian B.; Teng, Chao; Kunz, Stefan; Oldstone, Michael B. A.

LOCATION: Division of Virology, Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA, USA

JOURNAL: J. Clin. Invest. (Journal of Clinical Investigation) DATE: 2004

VOLUME: 113 NUMBER: 5 PAGES: 737-745 CODEN: JCINAO ISSN: 0021-9738

LANGUAGE: English PUBLISHER: American Society for Clinical Investigation SECTION:

CA215005 Immunochemistry

CA202XXX Mammalian Hormones

CA210XXX MICROBIAL, ALGAL, AND FUNGAL BIOCHEMISTRY

IDENTIFIERS: virus immunosuppression hematopoietic progenitor dendritic cell interferon

DESCRIPTORS:

Interferons...

α; viral infection of hematopoietic progenitors inhibits
interferon-dependent maturation and antigen-presenting function of
dendritic cells

Interferons...

β; viral infection of hematopoietic progenitors inhibits
interferon-dependent maturation and antigen-presenting function of
dendritic cells

Immunosuppression...

by viral infection is mediated via interferon-dependent inhibition of
dendritic cell maturation and costimulatory function

CD40(antigen)... CD80(antigen)... CD86(antigen)...

expression by dendritic cells is impaired by viral infection

Hemopoietins...

FLT3 ligand; viral infection of hematopoietic progenitors inhibits
maturation response to

Histocompatibility antigens...

H-2, class I; expression by dendritic cells is impaired by viral
infection

Histocompatibility antigens...

H-2, class II; expression by dendritic cells is impaired by viral
infection

Immunity...

immune surveillance; viral infection of hematopoietic progenitors
inhibits interferon-dependent maturation and antigen-presenting
function of dendritic cells in relation to escape from

Lymphocytic choriomeningitis virus...

interferon-dependent inhibition of dendritic cell maturation and
costimulatory function on infection by

Hematopoietic precursor cell...

stem cell; viral infection of hematopoietic progenitors inhibits
interferon-dependent maturation

Infection...

viral; of hematopoietic progenitors inhibits interferon-dependent
maturation and antigen-presenting function of dendritic cells

CAS REGISTRY NUMBERS:

83869-56-1 viral infection of hematopoietic progenitors inhibits
maturation response to

?

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES

?